[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4501
1. Farhat FS, Kattan J, Chahine GY, Younes FC, Nasr FL, Mroue RM, Ghosn MG: Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer. Med Oncol; 2010 Sep;27(3):722-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
  • Chemotherapy has a proven role in advanced and metastatic gastric cancer (AMGC) significantly improving quality of life and prolonging survival compared with best supportive care alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] N Engl J Med. 2008 Jan 3;358(1):36-46 [18172173.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):541-8 [1548519.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1585-95 [15520058.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10 ):1407-11 [16641916.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10 ):1514-9 [17473829.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):827-31 [2016625.001]
  • [Cites] Anticancer Res. 1992 Nov-Dec;12(6B):1983-8 [1295444.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):997-1001 [12966415.001]
  • [Cites] J Chemother. 2003 Jun;15(3):275-81 [12868555.001]
  • [Cites] Oncology. 2003;64(3):232-6 [12697963.001]
  • [Cites] Gastric Cancer. 2003;6(3):153-8 [14520528.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):221-31 [16770784.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] Ann Oncol. 2008 Jul;19 Suppl 5:v103-7 [18611865.001]
  • [Cites] Anticancer Drugs. 2003 Sep;14 (8):645-50 [14501387.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1269-75 [7999411.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92 (12 ):2122-8 [15942629.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Tumori. 1999 Jul-Aug;85(4):234-8 [10587023.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1281-6 [16622464.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):319-23 [10458249.001]
  • [Cites] Curr Oncol Rep. 2003 May;5(3):210-8 [12667418.001]
  • [Cites] Cancer. 1996 May 15;77(10):1978-85 [8640659.001]
  • [Cites] Oncol Rep. 2003 May-Jun;10 (3):687-91 [12684644.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4319-28 [15514373.001]
  • [Cites] Med Oncol. 2007;24(2):137-46 [17848736.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1773-81 [15550582.001]
  • (PMID = 19644778.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0H43101T0J / irinotecan; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


2. Yamashita T, Zeniya A, Otani S: Endoscopic submucosal dissection (ESD) using the needle knife: its superiority to ESD using the insulation-tipped diathermic knife in physicians intending to master ESD. Surg Laparosc Endosc Percutan Tech; 2010 Jun;20(3):180-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the absence of a supervisor, we conducted endoscopic submucosal dissection (ESD) procedures using the needle-knife and insulation-tipped (IT) diathermic knives for 516 gastric neoplasms in 443 Japanese patients with the diseases.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Diathermy / instrumentation. Dissection / instrumentation. Endoscopy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551819.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Zhang H, Fang DC, Lan CH, Luo YH: Helicobacter pylori infection induces apoptosis in gastric cancer cells through the mitochondrial pathway. J Gastroenterol Hepatol; 2007 Jul;22(7):1051-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori infection induces apoptosis in gastric cancer cells through the mitochondrial pathway.
  • BACKGROUND AND AIMS: To clarify the role of the mitochondrial pathway in apoptosis induced by H. pylori infection in gastric epithelial cells.
  • METHODS: Cells of a gastric adenocarcinoma cell line SGC-7,901 were co-cultured with H. pylori NCTC 11,637, with or without preincubation with the inhibitors of caspases -3, -8, and -9.
  • CONCLUSIONS: H. pylori infection induces apoptosis and the activation of caspases -3 and -9 in gastric cancer cells.
  • These findings suggest that the mitochondrial pathway may be the major pathway in H. pylori-induced apoptosis in gastric epithelial cells.
  • [MeSH-major] Adenocarcinoma / microbiology. Adenocarcinoma / pathology. Apoptosis. Caspase 3 / physiology. Caspase 9 / physiology. Helicobacter Infections / complications. Helicobacter pylori. Mitochondria / physiology. Stomach Neoplasms / microbiology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559379.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


Advertisement
4. Bilici M, Okcu N, Cayır K, Pirim I, Tekin SB, Gundogdu C: Distribution of HLA Tissue Groups in Patients with Gastric Cancer. Eurasian J Med; 2010 Apr;42(1):9-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of HLA Tissue Groups in Patients with Gastric Cancer.
  • OBJECTIVE: Gastric cancer is an important disease that is seen all over the world and that threats public health.
  • At the same time, gastric cancer is a heterogeneous disorder with multifactorial etiologies.
  • Recent studies have shown a significant association between HLA antigens and gastric adenocarcinoma.
  • The aim of the present study was to determine the distribution of HLA class I (HLA-A, B and C) and class II (HLA-DR, DQ and DP) antigens in Turkish patients with gastric adenocarcinoma.
  • MATERIALS AND METHODS: HLA alleles or HLA haplotypes associated with gastric cancer were established in the Turkish population using PSR-SSP analysis in 71 unrelated patients with gastric cancer and in 82 unrelated healthy controls.
  • RESULTS: The study revealed that the HLA-Cw5 antigen is more prevalent in patients with gastric cancer (p=0.042) and that the HLA-DRB1*15 antigen is more prevelent in the control group (p=0.021).
  • CONCLUSION: It is probable that HLA-Cw5 is a risk factor for gastric cancer whereas HLA-DRB1*15 plays a protective role for this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25610109.001).
  • [ISSN] 1308-8734
  • [Journal-full-title] The Eurasian journal of medicine
  • [ISO-abbreviation] Eurasian J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC4261300
  • [Keywords] NOTNLM ; Gastric cancer / HLA antigens / HLA-Cw5 / HLA-DRB1*15
  •  go-up   go-down


5. Kimura K, Nagasaka T, Hoshizima N, Sasamoto H, Notohara K, Takeda M, Kominami K, Iishii T, Tanaka N, Matsubara N: No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations. J Int Med Res; 2007 Jul-Aug;35(4):450-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No duplicate KRAS mutation is identified on the same allele in gastric or colorectal cancer cells with multiple KRAS mutations.
  • Codon 12 and 13 mutations in 170 colorectal cancer (CRC) and 66 gastric cancer (GC) specimens were analysed by an 'enriched' polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
  • The majority of colorectal and gastric cancer cells with KRAS mutations are homogeneous because they have the same KRAS mutation.
  • A few colorectal or gastric cancers, however, showed heterogeneity, as verified by the fact that single mutations were identified in the same allele.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. Genes, ras / genetics. Point Mutation. Proto-Oncogene Proteins / genetics. Stomach Neoplasms / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697521.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


6. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer; 2007;10(2):112-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
  • BACKGROUND: MK-1, the target molecule of FU-MK-1, is encoded by the GA733-2 gene, which is currently being used as a target in clinical trials for gastric, intestinal and biliary cancer treatment with monoclonal antibodies.
  • METHODS: The expression of p53 protein and MK-1 antigen was investigated in specimens from 42 patients with gastric carcinoma.
  • Of these 20 patients, 15 (52%) had tubular adenocarcinoma (TA) and 5 (38%) had signet ring cell carcinoma. p53 expression was more frequent in the tumors of male patients (55% vs 27%); in poorly differentiated TAs (60% vs 47% in well-to-moderately differentiated TAs); in smaller tumors (< or = 3 cm, 72% vs 43%-50% in larger tumors); in patients with a prominent inflammatory response (61% vs 21%; P < 0.02); and in patients with lymphatic vessel invasion (77% vs 34%; P < 0.02).
  • Most patients with p53- and MK-1-positive gastric carcinomas and those more than five metastatic lymph nodes had a poor prognosis.
  • CONCLUSION: The study found that the expression of both p53 and MK-1 was frequent in aggressive gastric carcinomas; however, extensive lymph node involvement (more than five nodes) was the only significant factor related to overall survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1994;424(4):343-7 [8205349.001]
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):211-6 [16616808.001]
  • [Cites] Arch Pathol Lab Med. 1977 Nov;101(11):568-71 [334106.001]
  • [Cites] Br J Cancer. 1993 Mar;67(3):589-93 [8439509.001]
  • [Cites] Int J Cancer. 1992 Apr 1;50(6):859-62 [1555884.001]
  • [Cites] Br J Cancer. 1994 May;69(5):943-6 [8180028.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2649-55 [7538044.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):653-61 [8398688.001]
  • [Cites] Hum Pathol. 1993 Jun;24(6):584-9 [8099338.001]
  • [Cites] Am J Clin Pathol. 1994 Feb;101(2):177-80 [8116572.001]
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):231-8 [10761711.001]
  • [Cites] Br J Cancer. 1992 Sep;66(3):558-62 [1520594.001]
  • [Cites] Virchows Arch. 1994;424(2):187-93 [8180781.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2A):769-76 [12014649.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4866-72 [3015400.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1247-53 [7977948.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2001-7 [12174877.001]
  • [Cites] Cancer Res. 1984 Sep;44(9):3952-6 [6744310.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):174-86 [8424417.001]
  • [Cites] Cancer. 1995 Sep 1;76(5):720-6 [8625172.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2439-47 [7680948.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2443-50 [1933781.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Histopathology. 2004 Apr;44(4):323-31 [15049897.001]
  • (PMID = 17577621.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Epithelial Cell Adhesion Molecule; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


7. Nazli O, Yaman I, Tansuğ T, Işgüder AS, Bozdag AD, Bölükbaşi H: Palliative surgery for advanced stage (stage IV) gastric adenocarcinoma. Hepatogastroenterology; 2007 Jan-Feb;54(73):298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative surgery for advanced stage (stage IV) gastric adenocarcinoma.
  • BACKGROUND/AIMS: The factors that effect resectability, major morbidity, early mortality, and survival in advanced stage gastric adenocarcinoma patients are evaluated.
  • METHODOLOGY: Records of 74 patients that underwent surgery for stage IV gastric adenocarcinoma in the Third Surgical Clinic of Izmir Atatürk Training Hospital between January 1997 and January 2004 were reviewed retrospectively.
  • Although early mortality was high in the palliative resection group, survival (mean 10.4 months, longest 25 months) was better compared to that of the unresectable gastric cancer group (mean 3.5 months, longest eight months).
  • CONCLUSIONS: A palliative gastric surgery may be applied to improve prognosis of advanced gastric cancer patients, even at the presence of peritoneal dissemination, hepatic metastases, N3 lymph node involvement, adjacent organ invasion, or poor differentiation of the tumor.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Palliative Care. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419279.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Oh MG, Cho SJ, Lee JH, Kook MC, Park SY: [A spongiform mass in the stomach: pyloric gland adenoma with a transition to adenocarcinoma]. Korean J Gastroenterol; 2010 Jul;56(1):1-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A spongiform mass in the stomach: pyloric gland adenoma with a transition to adenocarcinoma].
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Gastric Mucosa / pathology. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664311.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


9. Nakayama H, Ichinose S, Kato Y, Ito H, Masui K, Kameda Y: Long-term survival after a surgical resection of pulmonary metastases from gastric cancer: report of a case. Surg Today; 2008;38(2):150-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after a surgical resection of pulmonary metastases from gastric cancer: report of a case.
  • We describe a patient who survived for a prolonged period after repeated resections of pulmonary metastases from gastric cancer.
  • A 59-year-old man underwent a distal gastrectomy for gastric cancer.
  • A right middle lobectomy and a left lower lobectomy were performed for metastases from gastric cancer at 34 months and 82 months after the initial gastric resection, respectively.
  • To our knowledge, long-term survival after resection of pulmonary metastases from gastric cancer has only been reported in 3 patients previously.
  • [MeSH-major] Adenocarcinoma / surgery. Lung Neoplasms / surgery. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Today. 2004;34(9):784-7 [15338356.001]
  • [Cites] J Surg Oncol. 1987 Dec;36(4):239-42 [3695528.001]
  • [Cites] J Thorac Cardiovasc Surg. 1997 Jan;113(1):37-49 [9011700.001]
  • [Cites] J Surg Oncol. 1998 Nov;69(3):147-50 [9846500.001]
  • (PMID = 18239874.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 8
  •  go-up   go-down


10. Kunisaki C, Makino H, Takagawa R, Oshima T, Nagano Y, Fujii S, Otsuka Y, Akiyama H, Ono HA, Kosaka T, Ichikawa Y, Shimada H: Impact of palliative gastrectomy in patients with incurable advanced gastric cancer. Anticancer Res; 2008 Mar-Apr;28(2B):1309-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of palliative gastrectomy in patients with incurable advanced gastric cancer.
  • BACKGROUND: The efficacy of palliative gastrectomy for incurable advanced gastric cancer remains debatable.
  • CONCLUSION: A randomized controlled study should be conducted in advanced gastric cancer patients with a single non-curative factor to confirm the usefulness of palliative gastrectomy followed by chemotherapy shown here.
  • [MeSH-major] Adenocarcinoma / surgery. Palliative Care / methods. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18505071.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Lee CC, Wu CW, Lo SS, Chen JH, Li AF, Hsieh MC, Shen KH, Lui WY: Survival predictors in patients with node-negative gastric carcinoma. J Gastroenterol Hepatol; 2007 Jul;22(7):1014-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival predictors in patients with node-negative gastric carcinoma.
  • BACKGROUND: Presence or absence of nodal metastasis influences outcome of gastric cancer patients.
  • This study gives insight into survival predictors and clinicopathological features of node-negative gastric adenocarcinoma.
  • METHODS: Between 1988 and 1999, 689 gastric cancer patients without other cancer or gastrectomy for benign disease who underwent curative resection were enrolled in this study.
  • On univariate analysis, node-negative patients were characterized by frequent location in the lower two-thirds of the stomach (84.9%), tumor size less than 4 cm (63.5%), grossly superficial type (71.6%), more medullary stromal reaction (50.5%) and intestinal type (67.7%), tumor invasion confined to serosa (78.4%), less poorly differentiated cell type (43.2%), and less lymphovascular invasion (33.4%).
  • Multivariate analysis demonstrated that lymphovascular invasion (relative risk: 5.036) and depth of cancer invasion (relative risk: 4.404) were independent poor prognostic factors.
  • CONCLUSION: Patients with node-negative gastric adenocarcinoma had less disease progression and a favorable survival.
  • Lymphovascular invasion and depth of cancer invasion were two independent but correlated survival predictors.
  • [MeSH-major] Adenocarcinoma / mortality. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608847.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


12. Koehl GE, Wagner F, Stoeltzing O, Lang SA, Steinbauer M, Schlitt HJ, Geissler EK: Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation; 2007 Mar 15;83(5):607-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Mouse CT26 colon adenocarcinoma, B16 melanoma, and human TMK1 gastric adenocarcinoma cells were tested for in vitro growth in the presence of MMF.
  • [MeSH-minor] Adenocarcinoma. Animals. Aorta. Biological Availability. Cell Line, Tumor. Colonic Neoplasms. Endothelium, Vascular / drug effects. Endothelium, Vascular / physiology. Humans. Melanoma, Experimental. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Muscle, Smooth, Vascular / drug effects. Muscle, Smooth, Vascular / physiology. Stomach Neoplasms. Umbilical Veins

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MYCOPHENOLATE MOFETIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353782.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 9242ECW6R0 / mycophenolate mofetil; HU9DX48N0T / Mycophenolic Acid
  •  go-up   go-down


13. Hartwig W, Strobel O, Schneider L, Hackert T, Hesse C, Büchler MW, Werner J: Fundus rotation gastroplasty vs. Kirschner-Akiyama gastric tube in esophageal resection: comparison of perioperative and long-term results. World J Surg; 2008 Aug;32(8):1695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fundus rotation gastroplasty vs. Kirschner-Akiyama gastric tube in esophageal resection: comparison of perioperative and long-term results.
  • The aim of the present study was to compare the safety of FRG vs. the conventional Kirschner-Akiyama gastric tube in a large prospective clinical series.
  • METHODS: All patients with primary esophageal cancer who were to undergo esophageal resection at the authors' department were prospectively assessed.
  • Tumor type was squamous cell carcinoma in 51 patients and adenocarcinoma (AEG types I and II) in 60 patients.
  • CONCLUSION: This clinical series is the first to compare FRG and conventional gastric tube reconstruction after esophagectomy in esophageal cancer.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1997 Aug;226(2):169-73 [9296510.001]
  • [Cites] Ann Thorac Surg. 2005 Oct;80(4):1185-90 [16181838.001]
  • [Cites] Am J Surg. 1979 May;137(5):597-602 [453454.001]
  • [Cites] Surgery. 1996 Sep;120(3):542-6 [8784409.001]
  • [Cites] Eur J Cardiothorac Surg. 1999 Jun;15(6):769-73 [10431857.001]
  • [Cites] N Engl J Med. 1997 Jul 17;337(3):161-7 [9219702.001]
  • [Cites] J Thorac Cardiovasc Surg. 1992 Aug;104(2):395-400 [1495302.001]
  • [Cites] Surgery. 2001 Jan;129(1):103-9 [11150040.001]
  • [Cites] Surgery. 1986 May;99(5):614-22 [3704918.001]
  • [Cites] Dis Esophagus. 2001;14(3-4):212-7 [11869322.001]
  • [Cites] Ann Surg. 1994 Sep;220(3):364-72; discussion 372-3 [8092902.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):392-400; discussion 400-3 [10493486.001]
  • [Cites] Dig Surg. 2002;19(2):92-8 [11978992.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2001 Apr;7(2):75-8 [11371275.001]
  • [Cites] J Am Coll Surg. 1996 Mar;182(3):241-5 [8603244.001]
  • [Cites] World J Surg. 1997 Nov-Dec;21(9):992-7 [9361516.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):305-13 [11208820.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2006;20(5):893-906 [16997168.001]
  • [Cites] Br J Surg. 1976 Mar;63(3):206-9 [1260249.001]
  • [Cites] Am J Surg. 1993 Feb;165(2):273-6 [8427411.001]
  • [Cites] Eur J Surg. 2001 Feb;167(2):110-4 [11266249.001]
  • [Cites] Ann Thorac Surg. 1995 Aug;60(2):261-6; discussion 267 [7646084.001]
  • [Cites] Ann Surg Oncol. 2003 Aug;10(7):754-61 [12900366.001]
  • [Cites] Arch Surg. 2005 Jan;140(1):33-9 [15655203.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1125-8 [11571946.001]
  • [Cites] Ann Surg. 2003 Dec;238(6):803-12; discussion 812-4 [14631217.001]
  • [Cites] Ann Thorac Surg. 1992 Dec;54(6):1110-5 [1449294.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):68-75 [15213620.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):177-83 [12170022.001]
  • [Cites] Br J Surg. 1997 Jan;84(1):126-8 [9043476.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):241-6 [17245177.001]
  • (PMID = 18553046.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Tepes B: Can gastric cancer be prevented? J Physiol Pharmacol; 2009 Dec;60 Suppl 7:71-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can gastric cancer be prevented?
  • Gastric adenocarcinoma is the fourth most common malignancy worldwide and is globally the second leading cause of cancer-related deaths each year.
  • Among the risk factors are genetic factors (genetic diffuse gastric cancer - E-cadherin mutation (CDH1), pro- and anti-inflammatory cytokine genes and innate immune response gene polymorphisms), environmental factors (infection with the bacterium Helicobacter pylori (H. pylori), Epstein-Barr virus, nutrition: nitroso compounds, salt and antioxidants intake) and other factors (pernicious anemia, gastric polyps, gastric surgery, reproductive hormones, smoking).
  • The bacterium H. pylori has been found to be the major carcinogen in gastric cancer development.
  • Approximately 65%-80% of non-cardia gastric adenocarcinoma is attributable to H. pylori infection.
  • One percent of patients infected with H. pylori will develop gastric cancer.
  • American and European guidelines on the management of H. pylori infection recommend H. pylori eradication in all patients with atrophy and/or intestinal metaplasia and in all first-degree relatives of gastric cancer patients.
  • In the Asian Pacific Gastric Cancer Consensus, it was suggested for the first time that it is time for population-based screening and treatment of H. pylori infection in regions with gastric cancer incidence above 20/100000 per year.
  • Population screen and treat of H. pylori infection should be recommended in regions with gastric cancer incidence above 20/100000 per year.
  • This can be a good approach in H. pylori infected patients before they develop premalignant gastric lesions.
  • [MeSH-major] Adenocarcinoma / prevention & control. Stomach Neoplasms / prevention & control
  • [MeSH-minor] Animals. Early Detection of Cancer. Helicobacter Infections / complications. Helicobacter Infections / drug therapy. Helicobacter Infections / physiopathology. Helicobacter pylori. Humans. Mass Screening. Patient Education as Topic. Risk Factors. Stomach Diseases / physiopathology. Stomach Diseases / prevention & control. Stomach Diseases / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20388948.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 74
  •  go-up   go-down


15. Travaglione S, Fabbri A, Fiorentini C: The Rho-activating CNF1 toxin from pathogenic E. coli: a risk factor for human cancer development? Infect Agent Cancer; 2008;3:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Rho-activating CNF1 toxin from pathogenic E. coli: a risk factor for human cancer development?
  • Nowadays, there is increasing evidence that some pathogenic bacteria can contribute to specific stages of cancer development.
  • The concept that bacterial infection could be involved in carcinogenesis acquired a widespread interest with the discovery that H. pylori is able to establish chronic infections in the stomach and that this infection is associated with an increased risk of gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma.
  • Chronic infections triggered by bacteria can facilitate tumor initiation or progression since, during the course of infection, normal cell functions can come under the control of pathogen factors that directly manipulate the host regulatory pathways and the inflammatory reactions.Renowned publications have recently corroborated the molecular mechanisms that link bacterial infections, inflammation and cancer, indicating certain strains of Escherichia coli as a risk factor for patients with colon cancer. E. coli is a normal inhabitant of the human intestine that becomes highly pathogenic following the acquisition of virulence factors, including a protein toxin named cytotoxic necrotizing factor 1 (CNF1).
  • As cancer may arise through dysfunction of the same regulatory systems, it seems likely that CNF1-producing E. coli infections can contribute to tumor development.This review focuses on the aspects of CNF1 activity linked to cell transformation with the aim of contributing to the identification of a possible carcinogenic agent from the microbial world.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sci STKE. 2006 Oct 17;2006(357):re13 [17047224.001]
  • [Cites] Trends Mol Med. 2007 Mar;13(3):91-3 [17234453.001]
  • [Cites] Mol Biol Cell. 2007 Jul;18(7):2735-44 [17507655.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] FEMS Microbiol Lett. 1990 Jun 1;57(3):311-6 [2120109.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Toxicon. 1988;26(11):1047-56 [3072687.001]
  • [Cites] Infect Immun. 1983 Mar;39(3):1300-6 [6341235.001]
  • [Cites] Biochem Biophys Res Commun. 1984 Jan 30;118(2):587-93 [6367741.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Eur J Cancer Prev. 1995 Apr;4(2):187-93 [7767246.001]
  • [Cites] Lancet. 1994 Jan 8;343(8889):83-4 [7903779.001]
  • [Cites] Mol Microbiol. 1993 Sep;9(6):1247-54 [7934938.001]
  • [Cites] Lancet. 1979 Apr 14;1(8120):791-4 [86039.001]
  • [Cites] Science. 1996 Nov 1;274(5288):787-9 [8864120.001]
  • [Cites] Nature. 1997 Jun 12;387(6634):725-9 [9192900.001]
  • [Cites] J Clin Microbiol. 2000 Jan;38(1):7-12 [10618054.001]
  • [Cites] Lett Appl Microbiol. 2000 Mar;30(3):213-6 [10747253.001]
  • [Cites] Mol Biol Cell. 2000 May;11(5):1775-87 [10793151.001]
  • [Cites] Dig Dis Sci. 2000 May;45(5):900-3 [10795752.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1111-5 [10836997.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jul;2(7):530-7 [11433367.001]
  • [Cites] Mol Biol Cell. 2001 Jul;12(7):2061-73 [11452003.001]
  • [Cites] Mol Microbiol. 2001 Sep;41(6):1237-47 [11580831.001]
  • [Cites] Toxicon. 2001 Nov;39(11):1673-80 [11595630.001]
  • [Cites] Infect Immun. 2001 Nov;69(11):6839-45 [11598057.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):579-84 [11839578.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Trends Microbiol. 2002 Jun;10(6):293-9 [12088666.001]
  • [Cites] J Med Microbiol. 2002 Jul;51(7):548-56 [12132770.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42802-7 [12207028.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5865-9 [12228319.001]
  • [Cites] Cell. 2002 Nov 15;111(4):553-64 [12437928.001]
  • [Cites] Nature. 2002 Dec 12;420(6916):629-35 [12478284.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Cell Death Differ. 2003 Feb;10(2):147-52 [12700642.001]
  • [Cites] Infect Immun. 2003 Jul;71(7):4178-81 [12819113.001]
  • [Cites] Cancer J. 2004 May-Jun;10(3):145-52 [15285921.001]
  • [Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):412-21 [15300573.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):461-6 [15329734.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):297-305 [15380520.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1360-8 [15516338.001]
  • [Cites] Science. 2004 Nov 5;306(5698):966-8 [15528423.001]
  • [Cites] Nat Rev Microbiol. 2005 Apr;3(4):343-9 [15806096.001]
  • [Cites] Curr Top Microbiol Immunol. 2005;291:29-42 [15981458.001]
  • [Cites] Nat Rev Immunol. 2005 Oct;5(10):749-59 [16175180.001]
  • [Cites] Mol Microbiol. 1997 Jun;24(5):1061-70 [9220012.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19532-7 [9235957.001]
  • [Cites] Nature. 1997 Aug 14;388(6643):693-7 [9262406.001]
  • [Cites] Eur J Cancer Prev. 1997 Dec;6(6):557-9 [9496458.001]
  • [Cites] Infect Immun. 1998 May;66(5):2040-51 [9573087.001]
  • [Cites] Gut. 1998 Mar;42(3):351-6 [9577340.001]
  • [Cites] Annu Rev Immunol. 1998;16:225-60 [9597130.001]
  • [Cites] Exp Cell Res. 1998 Jul 10;242(1):341-50 [9665831.001]
  • [Cites] Infect Immun. 1999 Feb;67(2):496-503 [9916051.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1124-33 [14668491.001]
  • [Cites] J Clin Invest. 2004 Feb;113(3):321-33 [14755326.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):13-9 [14999150.001]
  • [Cites] Novartis Found Symp. 2004;256:215-21; discussion 221-6, 259-69 [15027493.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1 Suppl 3):64-73 [15052544.001]
  • [Cites] J Biol Chem. 2004 Aug 20;279(34):35849-57 [15152002.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):80-93 [15236175.001]
  • [Cites] Cell Death Differ. 1998 Sep;5(9):720-8 [10200530.001]
  • [Cites] Vet Res. 1999 Mar-Jun;30(2-3):221-33 [10367356.001]
  • [Cites] Mol Microbiol. 1999 Jul;33(1):108-18 [10411728.001]
  • [Cites] Nature. 1999 Sep 16;401(6750):293-7 [10499590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16339-44 [16258069.001]
  • [Cites] Cancer Sci. 2005 Dec;96(12):835-43 [16367902.001]
  • [Cites] Mol Cell. 2006 Mar 17;21(6):761-73 [16543146.001]
  • [Cites] FASEB J. 2006 Apr;20(6):606-9 [16581968.001]
  • [Cites] Mol Carcinog. 2006 Jun;45(6):355-61 [16673382.001]
  • [Cites] Infect Immun. 2006 Jul;74(7):3765-72 [16790748.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4706-16 [16892084.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4717-24 [16892085.001]
  • [Cites] Science. 2006 Aug 11;313(5788):848-51 [16902142.001]
  • [Cites] Autophagy. 2006 Oct-Dec;2(4):310-1 [16921260.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 30;72(9):1142-52 [16956585.001]
  • [Cites] Helicobacter. 2006 Oct;11(5):494-505 [16961812.001]
  • (PMID = 18336718.001).
  • [ISSN] 1750-9378
  • [Journal-full-title] Infectious agents and cancer
  • [ISO-abbreviation] Infect. Agents Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2323363
  •  go-up   go-down


16. Kato Y, Tsuyuki A, Kikuchi K, Fujishiro Y, Tanabe M, Watanabe M, Ozawa S, Kitajima M: Primary jejunal adenocarcinoma as part of multiple primary cancers of the digestive tract. J Gastroenterol Hepatol; 2008 Apr;23(4):673-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary jejunal adenocarcinoma as part of multiple primary cancers of the digestive tract.
  • We describe the first curative resection case of metachronous triple early cancers involving the jejunum as well as the stomach and esophagus.
  • The patient had undergone total gastrectomy for a gastric adenocarcinoma and subsequent esophagectomy for an esophageal squamous cell carcinoma.
  • A jejunal adenocarcinoma, the third primary, occurred at the blind stump of the jejunal limb of a Roux-en-Y esophagojejunostomy reconstructed previously.
  • The patient died from complications of acute pancreatitis 3 years after the last operation, without overt clinical signs of cancer recurrence.
  • Early diagnosis of each cancer was made possible by regular endoscopic follow-up and favorable anatomical location of each tumor, which were considered to allow less invasive surgery as well as to contribute to the favorable outcome.
  • [MeSH-major] Adenocarcinoma / diagnosis. Digestive System Neoplasms / diagnosis. Jejunal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis


17. Tang CP, Wang YW, Shiau YT, Lee RC, Lan KH, Chao Y: Gastropericardial fistula and Candida albicans pericarditis: a rare complication of gastric adenocarcinoma treated with radiation and chemotherapy. J Chin Med Assoc; 2009 Jul;72(7):374-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastropericardial fistula and Candida albicans pericarditis: a rare complication of gastric adenocarcinoma treated with radiation and chemotherapy.
  • Gastropericardial fistula is generally associated with benign gastric diseases and is an uncommon complication of gastric adenocarcinoma.
  • We report a 47-year-old man with gastric adenocarcinoma who had completed radiotherapy and was on scheduled chemotherapy, who presented with fever and chest pain.
  • Gastric adenocarcinoma complicated with gastropericardial fistula and Candida albicans pericarditis were diagnosed and treated successfully with conservative management.
  • However, follow-up panendoscopy 2 weeks later revealed a malignant ulcer with a fistula opening over the lesser curvature of the high body of the stomach.
  • This case demonstrates that first, panendoscopy may be safely performed in patients with gastropericardial fistula without significant risk of cardiac tamponade; second, although early diagnosis of gastropericardial fistula is generally important, delayed recognition may not lead to devastating outcomes even in the absence of surgical intervention.
  • [MeSH-major] Adenocarcinoma / complications. Candidiasis / etiology. Fistula / etiology. Gastric Fistula / etiology. Pericarditis / etiology. Pericardium. Stomach Neoplasms / complications
  • [MeSH-minor] Combined Modality Therapy. Endoscopy. Humans. Male. Middle Aged. Pneumopericardium / diagnosis. Pneumopericardium / etiology


18. Duan L, Wu AH, Sullivan-Halley J, Bernstein L: Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):526-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County.
  • OBJECTIVES: Concern has been expressed that antacid drugs increase the risk of esophageal and gastric adenocarcinomas.
  • METHODS: This population-based case-control study recruited patients with incident esophageal adenocarcinoma (n = 220), gastric cardiac adenocarcinoma (n = 277), or distal gastric adenocarcinoma (n = 441) diagnosed between 1992 and 1997, and 1,356 control participants in Los Angeles County.
  • RESULTS: Among participants who took nonprescription acid neutralizing agents for >3 years, the odds ratio for esophageal adenocarcinoma was 6.32 compared with never users (95% confidence interval, 3.14-12.69; P(trend) < 0.01).
  • Analyses stratified by history of physician diagnosed upper gastrointestinal (UGI) disorders revealed a greater increase in esophageal adenocarcinoma risk associated with nonprescription antacid use among persons with no UGI disorder than among those with an UGI disorder (homogeneity of trends P = 0.07).
  • Regular use of nonprescription acid neutralizing agents was not associated with risk of adenocarcinomas of the gastric cardia or distal stomach.
  • CONCLUSION: We found risk of esophageal adenocarcinoma was greater among long-term nonprescription acid neutralizing drugs in participants without physician-diagnosed UGI conditions than among those with these conditions; this may represent self medication for undiagnosed precursor conditions or it may be that nonprescription acid neutralizing drugs, taken without limitation on amount used when symptoms are most intense, may permit alkaline bile reflux into the lower esophagus, thereby increasing esophageal adenocarcinoma risk.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antacids / adverse effects. Esophageal Neoplasms / chemically induced. Stomach Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190141.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 5P30 ES07048; United States / NCI NIH HHS / CA / CA59636; United States / NCI NIH HHS / CN / N01 CN25403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antacids
  •  go-up   go-down


19. Jang SH, Lim JW, Kim H: Mechanism of beta-carotene-induced apoptosis of gastric cancer cells: involvement of ataxia-telangiectasia-mutated. Ann N Y Acad Sci; 2009 Aug;1171:156-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of beta-carotene-induced apoptosis of gastric cancer cells: involvement of ataxia-telangiectasia-mutated.
  • In the present study, we investigated whether a high concentration of beta-carotene induces apoptosis of gastric adenocarcinoma (AGS) cells and whether ATM is involved in beta-carotene-induced apoptosis of AGS cells.
  • Nuclear loss of ATM may be the underlying mechanism of beta-carotene-induced apoptosis of gastric cancer cells.
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Blotting, Western. Cell Line, Tumor. Cell Nucleus / metabolism. Cell Survival / drug effects. DNA Fragmentation. Dose-Response Relationship, Drug. Humans. Proto-Oncogene Proteins c-bcl-2 / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Transfection. Tumor Suppressor Protein p53 / metabolism. Vitamins / pharmacology

  • Genetic Alliance. consumer health - Ataxia.
  • Genetic Alliance. consumer health - Ataxia Telangiectasia.
  • Hazardous Substances Data Bank. BETA-CAROTENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19723050.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / Vitamins; 01YAE03M7J / beta Carotene; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


20. Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, Nordling S, Ristimäki A, Haglund C: Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res; 2005 Oct 15;11(20):7362-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR.
  • PURPOSE: Cyclooxygenase-2 (COX-2) promotes carcinogenesis and its expression associates with clinicopathologic characteristics in gastric cancer.
  • We evaluated the prognostic significance of COX-2 and HuR expressions in gastric cancer and whether there exists a link between HuR and COX-2 expressions.
  • EXPERIMENTAL DESIGN: The study included 342 consecutive patients with histologically confirmed gastric adenocarcinoma, of whom 321 patients had tissue specimens available for COX-2 and 316 for HuR immunohistochemistry.
  • TMK-1 gastric adenocarcinoma cells were treated with small interfering RNA against HuR and expressions of HuR and COX-2 were detected by immunofluorescence and Western blot analysis.
  • CONCLUSIONS: High COX-2 is an independent prognostic factor in gastric cancer.
  • Cytoplasmic expression of HuR associates with high COX-2 expression and with reduced survival, and tissue culture experiments show that HuR can regulate expression of COX-2 in gastric cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Antigens, Surface / metabolism. Cyclooxygenase 2 / metabolism. Membrane Proteins / metabolism. RNA-Binding Proteins / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243808.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / ELAV Proteins; 0 / ELAV-Like Protein 1; 0 / ELAVL1 protein, human; 0 / Membrane Proteins; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


21. Bralet MP, Letien K: [An unusual gastric metastasis]. Ann Pathol; 2006 Dec;26(6):454
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An unusual gastric metastasis].
  • [Transliterated title] Une métastase gastrique inhabituelle.
  • [MeSH-major] Stomach Neoplasms / pathology. Stomach Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Cell Nucleus / pathology. Female. Humans. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255906.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Lee JW, Jeong EG, Soung YH, Nam SW, Lee JY, Yoo NJ, Lee SH: Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas. Pathology; 2006 Aug;38(4):312-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of tumour suppressor Bax-interacting factor-1 (Bif-1), a Bax activator, in gastric carcinomas.
  • AIMS: Evasion of apoptosis is one of the hallmarks of cancer.
  • The aim of this study was to explore whether alteration of Bif-1 expression might be a characteristic of gastric cancer.
  • METHODS: We analysed the expression of Bif-1 protein in 60 gastric adenocarcinomas by immunohistochemistry using a tissue microarray approach.
  • RESULTS: In normal gastric mucosal cells, surface and glandular epithelial cells strongly expressed Bif-1.
  • While Bif-1 expression was detected in 24 cases (40%) of the gastric carcinomas, there was no Bif-1 immunostaining in the remaining 36 cancers.
  • CONCLUSION: The decreased expression of Bif-1 in malignant gastric epithelial cells compared with the normal mucosal cells suggests that loss of Bif-1 expression may play a role in gastric tumorigenesis, possibly by inhibiting the apoptosis mediated by Bif-1.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenocarcinoma / metabolism. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16916719.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / SH3GLB1 protein, human
  •  go-up   go-down


23. Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E, Vecchione L, Romano A, Martinelli E, Renda A, Ferraraccio F, Del Genio A, Ciardiello F, Galizia G: Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg; 2010 Mar;145(3):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study.
  • BACKGROUND: Adjuvant chemoradiotherapy does not represent the standard of care in patients with resected high-risk gastric cancer; however, results from phase 2 and randomized trials suggest improvement in overall survival.
  • We assessed the feasibility and toxic effects of chemoradiotherapy as adjuvant treatment in locally advanced gastric cancer.
  • PATIENTS: Twenty-nine patients with T4N+ or any TN23 gastric cancer previously treated with potentially curative surgery were enrolled.
  • MAIN OUTCOME MEASURES: Treatment toxic effects according to the National Cancer Institute-Common Toxicity Criteria classification, overall and disease-free survival rates, and identification of prognostic indicators.
  • CONCLUSION: A multimodal approach with FOLFOX-4 and radiotherapy is feasible and effective for the treatment of patients with resected high-risk gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2010 Mar;145(3):239 [20329345.001]
  • (PMID = 20231623.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hao H, Tsujimoto M, Tsubamoto H, Komori S, Hirota S: Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix. Pathol Int; 2010 Jul;60(7):528-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix.
  • Immunohistochemical phenotype of these glands was compared with three normal uterine endocervices and two cases of well-differentiated mucinous adenocarcinoma of the uterine cervix.
  • On the other hand, only glands of well-differentiated mucinous adenocarcinoma expressed human gastric mucin and showed high proliferative index of Ki-67.
  • Furthermore, diffuse distribution of estrogen and progesterone receptors, lack of human gastric mucin and low proliferative activity were distinct features for endocervicosis compared to well-differentiated mucinous adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Cesarean Section. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Phenotype. Pregnancy. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


25. Jung HJ, Lee HY, Kim BW, Jung SM, Kim HG, Ji JS, Choi H, Lee BI: Gastric Metastasis from Ovarian Adenocarcinoma Presenting as a Submucosal Tumor without Ulceration. Gut Liver; 2009 Sep;3(3):211-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Metastasis from Ovarian Adenocarcinoma Presenting as a Submucosal Tumor without Ulceration.
  • Metastatic gastric cancer is extremely rare and gastric metastasis from ovarian adenocarcinoma has rarely been reported.
  • We report a case of 49-year-old woman in which gastric metastasis from ovarian adenocarcinoma presented as a submucosal tumor without ulceration on endoscopic examination.
  • It was confirmed histopathologically as metastatic ovarian adenocarcinoma after endoscopic submucosal dissection (ESD) with enucleation.
  • Submucosal tumor of the stomach in patients with ovarian carcinoma should not be overlooked and ESD with enucleation may be a viable option when EUS with fine needle aspiration is not available.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 1996 Feb;28(2):249-53 [8739742.001]
  • [Cites] Gynecol Oncol. 1994 Oct;55(1):152-5 [7959258.001]
  • [Cites] Radiol Clin North Am. 1993 Nov;31(6):1359-73 [8210355.001]
  • [Cites] Am J Gastroenterol. 1992 Oct;87(10):1418-23 [1415098.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1596-600 [2311070.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):747-53 [15338368.001]
  • [Cites] J Ultrasound Med. 2004 Sep;23(9):1141-50 [15328428.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1561-6 [3621129.001]
  • (PMID = 20431748.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852710
  • [Keywords] NOTNLM ; Gastric metastasis / Ovarian adenocarcinoma / Submucosal tumor
  •  go-up   go-down


26. Sarıbaş Z, Demir H, Saltık Temizel IN, Simşek H, Ozen H, Akyön Y: [Detection of cagA prevalence in clinical isolates of Helicobacter pylori]. Mikrobiyol Bul; 2010 Jul;44(3):461-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori is a gram-negative, microaerophilic bacterium that colonizes human gastric mucosa and affects approximately 50% of the whole world population.
  • It has put the blame on gastric ulcer, duodenal ulcer, chronic atrophic gastritis, mucosa-associated lymphoid tissue lymphoma and stomach adenocarcinoma, as the etiological agent.
  • Recent studies have suggested that cagA positive H.pylori strains play a role in the development of gastric carcinoma.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063996.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


27. Kusanagi Y, Kojima A, Mikami Y, Kiyokawa T, Sudo T, Yamaguchi S, Nishimura R: Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype. Am J Pathol; 2010 Nov;177(5):2169-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of high-risk human papillomavirus (HPV) detection in endocervical adenocarcinoma with gastric morphology and phenotype.
  • A subset of endocervical-type mucinous adenocarcinomas (ACs) of the uterine cervix exhibit a gastric phenotype and morphology, as reported in cases of minimal deviation AC in which the presence of human papillomavirus (HPV) has been rarely detected.
  • To investigate the HPV-independent pathway of carcinogenesis in cases of gastric-type AC, we investigated the common high-risk HPV (hr-HPV) status in 52 nonsquamous cell carcinomas, using a PCR-based typing method and immunohistochemistry of p16INK4a (a cyclin-dependent kinase inhibitor that is overexpressed in both cancerous and precancerous cervical tissue, making it an ideal biomarker for cervical cancer cases).
  • Using novel morphological criteria, seven of 52 (13.5%) carcinomas were designated as gastric-type ACs, all of which were negative for both hr-HPV DNA and p16INK4a.
  • Our data suggests that gastric-type AC appears to represent an oncogenic hr-HPV-independent neoplasm and therefore is a potential pitfall of HPV DNA testing and vaccination.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology


28. Bigot P, Desbois E, Benoist N, Besnier L, Moui Y: [Isolated pain of the hand revealing a metastatic tumor of the hand. Report of a case]. Chir Main; 2007 Dec;26(6):300-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Acrométastase révélée par une douleur isolée de la main. A propos d'un cas.
  • We describe a patient with gastric cancer.
  • OBSERVATION: A 64-year-old man in remission of a gastric adenocarcinoma treated surgically one year previously was admitted to hospital for a pain of the right hand associated with an edema.
  • The anatomopathologic examination revealed an osseous metastasis of a gastric adenocarcinoma.
  • The patient died five months after the diagnosis of acrometastasis.
  • Evolution during acrometastasis of gastric cancer is the same one as in the other acrometastases.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Hand. Metacarpal Bones. Pain / etiology
  • [MeSH-minor] Biopsy. Combined Modality Therapy. Humans. Male. Middle Aged. Osteolysis / etiology. Prognosis. Radiotherapy Dosage. Stomach Neoplasms. Time Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023234.001).
  • [ISSN] 1297-3203
  • [Journal-full-title] Chirurgie de la main
  • [ISO-abbreviation] Chir Main
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


29. Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J: Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer; 2006 Jul 3;95(1):118-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden.
  • In a population-based cohort study of all women aged over 50 years with breast cancer in the Swedish Cancer Register in 1961-2003, those diagnosed before 31 December 1987 were regarded as unexposed to tamoxifen, whereas those diagnosed after that date were considered potentially exposed.
  • Crosslinkages within the Cancer Register and the Registers of Death and Emigration enabled follow-up.
  • Standardised incidence ratios (SIRs) of oesophageal and gastric cancer represented relative risks.
  • Among 138 885 cohort members contributing with 1 075 724 person-years of follow-up, we found a nonsignificantly increased risk of oesophageal adenocarcinoma during the potential tamoxifen exposure period (SIR 1.60, 95% confidence interval (CI) 0.83-3.08), but the risk estimates decreased with increasing latency interval.
  • No increased risk of cardia adenocarcinoma was identified in either period.
  • The risk of non-cardia gastric adenocarcinoma was increased in the potential tamoxifen period (SIR 1.27, 1.03-1.57), and almost doubled (SIR 1.86, 95% CI 1.10-3.14) in the period of longest latency (10-14 years).
  • An increased risk of tobacco-related tumours, that is, oesophageal squamous-cell carcinoma and lung cancer, was limited to the unexposed cohort, indicating that confounding by smoking might explain the increased SIR during the unexposed period.
  • We concluded that there might be a link between tamoxifen and risk of non-cardia gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Breast Neoplasms / drug therapy. Carcinoma, Squamous Cell / chemically induced. Esophageal Neoplasms / chemically induced. Lung Neoplasms / chemically induced. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):479-85 [16552198.001]
  • [Cites] Ann Oncol. 2000 Dec;11(12):1537-43 [11205460.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):3-15 [12160084.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):529-33 [4055127.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):117-20 [2563046.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1007-10 [2667745.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1013-7 [2072407.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] J Natl Cancer Inst. 1995 May 3;87(9):645-51 [7752269.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 19;88(12):832-4 [8637050.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Cancer Causes Control. 2005 Apr;16(3):285-94 [15947880.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):859-61 [16189516.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):136-41 [16404367.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • (PMID = 16755290.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Other-IDs] NLM/ PMC2360495
  •  go-up   go-down


30. Lee JH, Ryu KW, Lee JS, Lee JR, Kim CG, Choi IJ, Park SR, Kook MC, Kim YW, Bae JM: Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly. J Surg Oncol; 2007 May 1;95(6):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decisions for extent of gastric surgery in gastric cancer patients: younger patients require more attention than the elderly.
  • BACKGROUND AND OBJECTIVES: There is a prevailing belief that young patients with gastric adenocarcinomas have a more aggressive disease.
  • METHODS: We reviewed the prospectively collected database of 753 gastric adenocarcinomas patients who had undergone curative gastrectomy.
  • CONCLUSIONS: The present study showed that intra-operative under-staging was more common in young patients with gastric cancer, especially with stage I disease.
  • This finding raises the concern for inaccurate diagnosis and surgical under treatment in younger patients with stage I gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17195172.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bai JG, Lv Y, Dang CX: Adenocarcinoma of the Esophagogastric Junction in China according to Siewert's classification. Jpn J Clin Oncol; 2006 Jun;36(6):364-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the Esophagogastric Junction in China according to Siewert's classification.
  • BACKGROUND: There had never been a clear definition of the cancer of cardia before Siewert's classification, which was proposed in 1996 and approved in 1997 at the second International Gastric Cancer Congress in Munich.
  • On the basis of the classification, this study aims to research into the clinicopathological characteristics and surgical modes of adenocarcinoma of the esophagogastric junction in China.
  • METHODS: The study reviewed the data of the distal esophageal cancer, the cancer of cardia and the proximal gastric cancer at the First Hospital of Xi'an Jiaotong University from January 1995 to December 1999.
  • RESULTS: Among the 203 patients, there were 29 patients with adenocarcinoma of the distal esophagus (Type I); 80 patients with true carcinoma of cardia (Type II); and 94 patients with subcardial carcinoma (Type III).
  • [MeSH-major] Adenocarcinoma / classification. Esophageal Neoplasms / classification. Esophagectomy. Esophagogastric Junction. Lymph Node Excision. Stomach Neoplasms / classification
  • [MeSH-minor] Barrett Esophagus / pathology. Cardia. China / epidemiology. Female. Gastrectomy. Gastric Mucosa / pathology. Humans. Lymph Nodes / pathology. Male. Metaplasia. Middle Aged. Morbidity. Postoperative Complications / etiology. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16766566.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Mita M, Satoh M, Shimada A, Okajima M, Azuma S, Suzuki JS, Sakabe K, Hara S, Himeno S: Metallothionein is a crucial protective factor against Helicobacter pylori-induced gastric erosive lesions in a mouse model. Am J Physiol Gastrointest Liver Physiol; 2008 Apr;294(4):G877-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein is a crucial protective factor against Helicobacter pylori-induced gastric erosive lesions in a mouse model.
  • Infection with the gastric pathogen Helicobacter pylori (H. pylori) causes chronic gastritis, peptic ulcer, and gastric adenocarcinoma.
  • In the present study, we examined the role of MT in the protection against H. pylori-induced gastric injury using MT-null mice.
  • Furthermore, activation of NF-kappaB and expression of NF-kappaB-mediated chemokines such as macrophage inflammatory protein-1alpha and monocytes chemoattractant protein-1 in gastric cells were markedly higher in MT-null mice than in wild-type mice.
  • These results suggest that MT in the gastric mucosa might play an important role in the protection against H. pylori-induced gastric ulceration.
  • [MeSH-major] Cytoprotection. Gastric Mucosa / metabolism. Helicobacter Infections / complications. Helicobacter pylori / pathogenicity. Metallothionein / metabolism. Stomach Ulcer / prevention & control

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18239062.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ccl2 protein, mouse; 0 / Ccl3 protein, mouse; 0 / Chemokine CCL2; 0 / Chemokine CCL3; 0 / Mt2 protein, mouse; 0 / NF-kappa B; 0 / Reactive Oxygen Species; 0 / metallothionein-1, mouse; 9038-94-2 / Metallothionein
  •  go-up   go-down


33. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR: Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst; 2006 Oct 18;98(20):1445-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity.
  • BACKGROUND: Colonization with Helicobacter pylori is a risk factor for gastric adenocarcinoma, but the magnitude of this association and its relationship to anatomic location of the cancer, duration of follow-up, age at diagnosis, histologic subtype, and H. pylori strain differences are less clear.
  • METHODS: Case and control subjects were selected from the 29,133 50- to 69-year-old males recruited into the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
  • From 1985 to 1999, 243 incident cases of gastric adenocarcinoma were diagnosed in cohort members.
  • Serum samples from 234 case subjects (173 with noncardia gastric cancers and 61 with gastric cardia cancers) and 234 age-matched control subjects were assayed for antibodies against H. pylori whole-cell and CagA antigens.
  • We fit conditional logistic regression models to estimate the unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association of H. pylori seropositivity, defined as seropositivity to either whole-cell or CagA antigens, with noncardia gastric and gastric cardia cancers.
  • RESULTS: H. pylori seropositivity was strongly associated with the risk of noncardia gastric cancer (adjusted OR = 7.9, 95% CI = 3.0 to 20.9) but was inversely associated with the risk of gastric cardia cancer (adjusted OR = 0.31, 95% CI = 0.11 to 0.89). H. pylori seropositivity rates did not vary statistically significantly by length of follow-up, age at diagnosis, or histologic subtype.
  • A calculation of rates showed that the absolute risks of noncardia gastric and cardia gastric adenocarcinomas in the H. pylori-positive participants of this cohort would be 63 and 12 per 100,000 person-years, respectively, whereas corresponding rates in H. pylori-negative participants would be 8 and 37 per 100,000 person-years, respectively.
  • CONCLUSION: H. pylori is a strong risk factor for noncardia gastric cancer but is inversely associated with the risk of gastric cardia cancer.
  • These findings bolster the hypothesis that decreasing H. pylori prevalence during the past century may have contributed to lower rates of noncardia cancer and higher rates of cardia cancer in Western countries.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / microbiology. Cardia. Helicobacter Infections / complications. Helicobacter Infections / epidemiology. Helicobacter pylori. Stomach Neoplasms / epidemiology. Stomach Neoplasms / microbiology


34. Suleyman H, Cadirci E, Albayrak A, Halici Z, Gundogdu C, Hacimuftuoglu A: Occurrence of anticancer activity of prednisolone via adrenalectomy and inhibition of adrenaline in rats. Int J Cancer; 2010 Apr 1;126(7):1740-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the anticancer effect of prednisolone was investigated using rats with normal endogen adrenaline levels (intact), reduced adrenaline levels (metyrosine-induced) and adrenaline deficiency (adrenalectomized) via gastric adenocarcinoma model.
  • Gastric adenocarcinoma was induced with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).
  • According to our experimental results, prednisolone could not prevent MNNG-induced adenocarcinoma when used alone in intact rats.
  • There were neither macroscopic nor microscopic signs of cancer in the rat groups that received metyrosine and prednisolone.
  • There was no adenocarcinoma genesis in the stomachs of adrenalectomized rats that received prednisolone alone.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adrenalectomy. Anti-Inflammatory Agents / pharmacology. Antineoplastic Agents / pharmacology. Epinephrine / metabolism. Prednisolone / pharmacology. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711350.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 0 / Catecholamines; 12H3O2UGSF / Methylnitronitrosoguanidine; 9PHQ9Y1OLM / Prednisolone; YKH834O4BH / Epinephrine
  •  go-up   go-down


35. Takeo H, Matsukuma S: Gastric tube cancer: immunohistochemical study of 10 lesions in six patients. J Gastroenterol Hepatol; 2007 Jan;22(1):23-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric tube cancer: immunohistochemical study of 10 lesions in six patients.
  • BACKGROUND AND AIM: Gastric tube cancer (GTC), defined as carcinoma arising in the reconstructed gastric tube after esophagectomy, has been increasingly reported, but its pathogenesis remains unclear.
  • METHODS: In addition to examination of the clinicopathological features of GTCs, the adjacent gastric tube mucosa was also evaluated immunohistochemically using gastric foveolar markers (MUC5AC and human gastric mucin), pyloric gland markers (MUC6 and M-GGMC-1), and intestinal markers (MUC2 and CD10).
  • All GTCs were located on the middle to lower portion of the gastric tube.
  • Nine GTCs had tubular and/or papillary adenocarcinoma components, and another was signet-ring cell carcinoma.
  • Metaplastic goblet cells adjacent to five GTCs expressed both gastric and intestinal markers, which were similar to the corresponding GTC cells, indicating a close association between the GTCs and metaplastic goblet cells.
  • CONCLUSION: Pathogenesis of GTCs could be identical to that of ordinary gastric cancer.
  • Cancerous multiplicity associated with esophageal cancer may also play a role in the development of GTCs.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Esophagectomy. Gastric Mucins / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Mucin 5AC. Mucins / metabolism. Phenotype. Reconstructive Surgical Procedures

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201876.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gastric Mucins; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins
  •  go-up   go-down


36. Shin VY, Jin HC, Ng EK, Yu J, Leung WK, Cho CH, Sung JJ: Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways. Toxicol Appl Pharmacol; 2008 Dec 1;233(2):254-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induce cyclooxygenase-2 activity in human gastric cancer cells: Involvement of nicotinic acetylcholine receptor (nAChR) and beta-adrenergic receptor signaling pathways.
  • Nicotine and its derivative, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), are the two important components in cigarette smoke that contributes to cancer development.
  • However, the molecular mechanism(s) by which nicotine or NNK promotes gastric carcinogenesis remains largely unknown.
  • In addition, nicotine and NNK mediated COX-2 induction via different receptors to modulate several G1/S transition regulatory proteins and promote gastric cancer cell growth.
  • These results pointed to the importance of adrenergic and nicotinic receptors in gastric tumor growth through MAPK/COX-2 activation, which may perhaps provide a chemoprevention strategy for cigarette smoke-related gastric carcinogenesis.
  • [MeSH-major] Carcinogens / toxicity. Cyclooxygenase 2 / drug effects. Nicotine / toxicity. Nitrosamines / toxicity. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Bungarotoxins / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin D1 / metabolism. Dinoprostone / metabolism. Gene Expression Regulation / drug effects. Humans. Propranolol / pharmacology. Receptors, Adrenergic, beta / drug effects. Receptors, Adrenergic, beta / metabolism. Receptors, Nicotinic / drug effects. Receptors, Nicotinic / metabolism. Signal Transduction / drug effects. alpha7 Nicotinic Acetylcholine Receptor. p38 Mitogen-Activated Protein Kinases / drug effects. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. NICOTINE .
  • Hazardous Substances Data Bank. 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18805435.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bungarotoxins; 0 / Carcinogens; 0 / Chrna7 protein, human; 0 / Nitrosamines; 0 / Receptors, Adrenergic, beta; 0 / Receptors, Nicotinic; 0 / alpha7 Nicotinic Acetylcholine Receptor; 136601-57-5 / Cyclin D1; 64091-91-4 / 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone; 6M3C89ZY6R / Nicotine; 9Y8NXQ24VQ / Propranolol; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


37. Ikeda O, Toh Y, Aoki Y, Harimoto N, Taomoto J, Masuda T, Ohga T, Adachi E, Sakaguchi Y, Okamura T, Hirahashi M, Nishiyama K, Baba H: Multiple and metachronous esophageal intramural metastases from a gastric adenocarcinoma. Gastric Cancer; 2008;11(2):119-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple and metachronous esophageal intramural metastases from a gastric adenocarcinoma.
  • Intramural metastasis from gastric cancer to the esophageal wall, however, has rarely been reported.
  • We herein report a rare case of a 46-year-old man with an elevated esophageal lesion, resembling a 0-IIa-type esophageal cancer, which was discovered 13 months after a total gastrectomy performed for gastric cancer.
  • The esophageal tumor, resected by endoscopic mucosal resection (EMR), was an adenocarcinoma with the same histology as the previously resected primary gastric cancer, and it showed massive lymphatic permeation.
  • We therefore considered the esophageal tumor to be a systemic expansion of the primary gastric cancer, and we administered the anticancer drug, S-1.
  • Esophageal intramural metastases from a gastric cancer imply a systemic expansion of the gastric cancer, and portend a poor prognosis.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1996 Jan;20(1):32-7 [8588409.001]
  • [Cites] Surg Today. 1998;28(11):1160-2 [9851624.001]
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1346-51 [16552799.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:28-33 [12775017.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1816-9 [2317758.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:24-7 [12775016.001]
  • [Cites] Endoscopy. 2002 May;34(5):418-20 [11972277.001]
  • [Cites] J Surg Oncol. 1994 Sep;57(1):17-21 [8065145.001]
  • (PMID = 18595019.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Kim JH, Kim SS, Byun SW, Chang YJ, Kim JS, Kim JK, Cho HJ, Lim KW, Jung ES: [Double strand break of DNA in gastric adenoma and adenocarcinoma]. Korean J Gastroenterol; 2010 Jan;55(1):19-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Double strand break of DNA in gastric adenoma and adenocarcinoma].
  • The aim of this study was to define the differences in expression of 53BP1 and gamma-H2AX, the markers of DSB, among normal, gastric adenoma, and gastric adenocarcinoma tissues.
  • METHODS: Tissue microarray was made with the tissues taken from 121 patients who underwent gastrectomy for gastric adenocarcinoma, and 51 patients who underwent endoscopic mucosal resection for gastric adenoma.
  • The normal tissues were collected from histologically confirmed tissues with no cellular atypia obtained from the patients with gastric adenocarcinoma.
  • RESULTS: In gastric carcinoma cells, 53BP1 and gamma-H2AX were highly expressed as compared to normal epithelial cells and gastric adenoma (p<0.01).
  • There were no differences in the expression of 53BP1 and gamma-H2AX between normal epithelium and gastric adenoma.
  • The expression of 53BP1 and gamma-H2AX were not significantly different according to the clinicopathologic parameters in the patients with gastric adenocarcinoma.
  • CONCLUSIONS: The DSB in DNA seems to be associated with the development of gastric adenocarcinoma, but does not affect the premalignant adenoma cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. DNA Breaks, Double-Stranded. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098063.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / H2AFX protein, human; 0 / Histones; 0 / Intracellular Signaling Peptides and Proteins; 0 / TP53BP1 protein, human; 0 / Tumor Suppressor p53-Binding Protein 1
  •  go-up   go-down


39. Persiani R, Rausei S, Biondi A, Boccia S, Cananzi F, D'Ugo D: Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer. Eur J Surg Oncol; 2008 May;34(5):519-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ratio of metastatic lymph nodes: impact on staging and survival of gastric cancer.
  • AIMS: No consensus exists on the level and number of lymph nodes to be dissected and examined for accurate staging of patients with resectable gastric cancer.
  • METHODS: The postoperative survival of 247 patients with gastric cancer who underwent gastrectomy was analyzed.
  • [MeSH-major] Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging / methods. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624713.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


41. Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zieliński J, Szajewski M, Jasiński W, Kawecki K, Wojtacki J: Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers; 2010;29(5):207-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of HER2 in colorectal cancer does not correlate with prognosis.
  • Estimation of HER2 membranous expression is routinely used in breast and gastric cancers, as both a prognostic and a predictive factor.
  • To date there is no evidence for similar application of HER2 expression in colorectal cancer (CRC) cells.
  • HER2 expression in resectable colorectal adenocarcinoma cells was evaluated by immunohistochemistry in specimens taken from 202 patients.
  • The percentage of cancer cells with membranous or cytoplasmatic reactions and the staining intensity of the reaction in the whole cell were recorded.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Biomarkers, Tumor / biosynthesis. Colorectal Neoplasms / pathology. Receptor, ErbB-2 / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21206005.001).
  • [ISSN] 1875-8630
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC3835377
  •  go-up   go-down


42. Gao C, Zhang Z, Liu W, Xiao S, Gu W, Lu H: Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer; 2010 Jan 1;116(1):41-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer.
  • BACKGROUND: Poor expression of microRNAs (miRs) reportedly plays an important role in gastric carcinogenesis.
  • Large-scale microarray assays have indicated that there is significant down-regulation of miR-218 in gastric cancer. miR-218 also was decreased specifically in human papillomavirus-positive cell lines, cervical lesions, and cervical cancer tissues and in bronchial airway epithelium in smokers.
  • However, its role in carcinogenesis remains unclear, especially in Helicobacter pylori (H. pylori)-associated gastric cancer.
  • METHODS: miR-218 levels were evaluated in 20 noncardia gastric cancer tissues, in 10 H. pylori-infected and 8 uninfected normal gastric biopsies, and in the human gastric epithelial cancer cell line AGS using TaqMan quantitative real-time polymerase chain reaction analysis.
  • RESULTS: miR-218 expression was reduced significantly in gastric cancer tissues, in H. pylori-infected gastric mucosa, and in H. pylori-infected AGS cells.
  • [MeSH-major] Adenocarcinoma / genetics. Down-Regulation. MicroRNAs / metabolism. NF-kappa B / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Apoptosis. Cell Line, Tumor. Cell Proliferation. Cyclooxygenase 2 / genetics. Gastric Mucosa / metabolism. Gastric Mucosa / microbiology. Helicobacter Infections / genetics. Helicobacter pylori. Humans. Receptor, Epidermal Growth Factor. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Cancer Society.
  • (PMID = 19890957.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN218 microRNA, human; 0 / MicroRNAs; 0 / NF-kappa B; 0 / Transcription Factors; 0 / VOPP1 protein, human; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


43. Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M: The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol; 2008;29(4):245-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines.
  • BACKGROUND/AIMS: It has been demonstrated that substance P (SP) and neurokinin-1 (NK-1) receptor antagonist L-733,060 induces cell proliferation and inhibition, respectively, in several human cancer cell lines.
  • At present, it is unknown whether such actions are exerted on human gastric and colon adenocarcinomas.
  • We carried out an in vitro study of the growth-inhibitory capacity of L-733,060 against human gastric and colon adenocarcinomas.
  • Immunohistochemistry was used to demonstrate NK-1 receptors in primary human gastric and colon adenocarcinomas.
  • RESULTS: We observed the presence of several NK-1 receptor isoforms in human gastric and colon adenocarcinomas.
  • In both human primary gastric and colon adenocarcinomas, a high density of NK-1 receptors was observed.
  • CONCLUSIONS: We demonstrated that NK-1 receptors were expressed in 23132/37 and SW-403 cell lines and in human primary gastric and colon adenocarcinomas, that SP is a mitogen and that the antitumor action of L-733,060 on both human cell lines occurs through the NK-1 receptor.
  • These data suggest that the NK-1 receptor is a new and promising target in the treatment of human gastrointestinal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Antineoplastic Agents / pharmacology. Colonic Neoplasms / chemistry. Mitogens / pharmacology. Piperidines / pharmacology. Receptors, Neurokinin-1 / analysis. Stomach Neoplasms / chemistry. Substance P / pharmacology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18781096.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Mitogens; 0 / Neurokinin-1 Receptor Antagonists; 0 / Piperidines; 0 / Receptors, Neurokinin-1; 148700-85-0 / 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine; 33507-63-0 / Substance P
  •  go-up   go-down


44. Seo JH, Kim KH, Kim H: Role of proteinase-activated receptor-2 on cyclooxygenase-2 expression in H. pylori-infected gastric epithelial cells. Ann N Y Acad Sci; 2007 Jan;1096:29-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of proteinase-activated receptor-2 on cyclooxygenase-2 expression in H. pylori-infected gastric epithelial cells.
  • Proteinase-activated receptor-2 (PAR-2) belongs to a novel subfamily of G protein-coupled receptors with seven-transmembrane domains.
  • The presence of trypsin has been shown in human stomach.
  • Cyclooxygenase-2 (COX-2) is induced by inflammatory cytokines, growth factors, gastrin, and reactive oxygen species in gastric epithelial cells, which may lead to mutagenesis and subsequent metaplasia, dysplasia, and cancer formation.
  • We investigated whether PAR-2 is activated in H. pylori (HP99)-infected cells, which is related to COX-2 induction in gastric epithelial cells.
  • After treatment of H. pylori to AGS (gastric adenocarcinoma) cells at a bacteria/cell ratio of 100:1, we determine the expression and the activation of PAR-2 and the expression of COX-2.
  • PAR-2 agonist peptide augmented H. pylori-induced COX-2 expression in AGS cells. H. pylori induces COX-2 expression, which is mediated by both activation and expression of PAR-2 in gastric epithelial cells.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Epithelium / microbiology. Gastric Mucosa / microbiology. Gene Expression Regulation, Enzymologic. Receptor, PAR-2 / biosynthesis. Receptor, PAR-2 / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405913.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptides; 0 / RNA, Messenger; 0 / Receptor, PAR-2; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


45. Wang HZ, Wang HB, Gao H: [Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Oct;27(10):927-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction].
  • OBJECTIVE: To evaluate the therapeutic and adverse reactions of integrative Chinese and Western medicine (ICWM) for treatment of advanced gastric carcinoma.
  • METHODS: Sixty-six patients with advanced gastric carcinoma were randomized into two groups.
  • CONCLUSION: Although treatment of ICWM for advanced gastric carcinoma cannot improve response rate, it could alleviate the adverse reactions of the treatment, improve quality of life and prolong the survival rate in patients.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990465.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Taxoids; 0 / fuzheng hewei; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Shinto O, Yashiro M, Kawajiri H, Shimizu K, Shimizu T, Miwa A, Hirakawa K: Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice. Cancer Sci; 2010 Aug;101(8):1846-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination effect of a TGF-beta receptor kinase inhibitor with 5-FU analog S1 on lymph node metastasis of scirrhous gastric cancer in mice.
  • Transforming growth factor-beta (TGF-beta) signals are closely associated with the distant metastases of gastric cancer.
  • The aim of this study was to clarify the effect of a TGF-beta receptor I (TbetaR-I) phosphorylation inhibitor, Ki26894, in combination with anticancer drugs, on the lymph node (LN) metastasis of scirrhous gastric cancer.
  • The human scirrhous gastric cancer cell line OCUM-2MLN and the human gastric fibroblasts NF-33 were used.
  • Gastric cancer models established by orthotopic inoculation of OCUM-2MLN cells showed diffusely infiltrating gastric adenocarcinoma accompanied by LN metastases.
  • Ki26894 inhibited the Smad2 phosphorylation of cancer cells and decreased the extent of lymphatic involvement, compared with the control or S1 only group.
  • These findings suggested that the TbetaR-I kinase inhibitor with S1 is useful for the treatment of scirrhous gastric carcinoma with LN metastasis. (Cancer Sci 2010).
  • [MeSH-major] Activin Receptors, Type I / antagonists & inhibitors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Oxonic Acid / administration & dosage. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Receptors, Transforming Growth Factor beta / antagonists & inhibitors. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518790.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Ki26894; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad2 Protein; 0 / Transforming Growth Factor beta1; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.7.1.11 / TGF-beta type I receptor; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / Activin Receptors, Type I
  •  go-up   go-down


47. González-Moreno S: Peritoneal dissemination: a pending issue in gastric cancer worth exploring. Ann Surg Oncol; 2009 Dec;16(12):3217-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal dissemination: a pending issue in gastric cancer worth exploring.
  • [MeSH-major] Adenocarcinoma / secondary. Peritoneal Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1238-47 [11677938.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):20-6 [14718269.001]
  • [Cites] Br J Surg. 2005 Mar;92(3):370-5 [15739249.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):661-5 [16621433.001]
  • [Cites] Ann Surg Oncol. 2009 Dec;16(12):3227-36 [19777180.001]
  • [CommentOn] Ann Surg Oncol. 2009 Dec;16(12):3227-36 [19777180.001]
  • (PMID = 19777178.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  •  go-up   go-down


48. Lee CH, Bang SH, Lee SK, Song KY, Lee IC: Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ. World J Gastroenterol; 2005 Apr 7;11(13):1937-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ.
  • AIM: To analyze the expression profiles of premalignant and/or preclinical lesions of gastric cancers.
  • METHODS: We analyzed the expression profiles of normal gastric pit, tubular adenoma and carcinoma in situ using microdissected cells from routine gastric biopsies.
  • Differentially expressed genes were grouped according to patterns of the sequential changes for the 'tendency analysis' in the gastric mucosa-adenoma-carcinoma sequence.
  • CONCLUSION: Groups of genes are shown to reflect the sequential expression changes in the early carcinogenic steps of stomach cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma in Situ / genetics. Gene Expression Profiling. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15800983.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305714
  •  go-up   go-down


49. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Intestinal adenocarcinomas were analysed immunohistochemically for the presence of ER alpha, beta and beta cx.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cohort Studies. Disease Progression. Female. Gastric Mucosa / metabolism. Humans. Middle Aged. Receptors, Estrogen / metabolism. Risk Factors. Stomach / metabolism. Sweden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


50. García Rodríguez LA, Lagergren J, Lindblad M: Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut; 2006 Nov;55(11):1538-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK.
  • BACKGROUND: Gastric acid suppressing drugs (that is, histamine(2) receptor antagonists and proton pump inhibitors) could affect the risk of oesophageal or gastric adenocarcinoma but few studies are available.
  • AIMS: To study the association between long term treatment with acid suppressing drugs and the risk of oesophageal or gastric adenocarcinoma.
  • RESULTS: In 4 340 207 person years of follow up, 287 patients with oesophageal adenocarcinoma, 195 with gastric cardia adenocarcinoma, and 327 with gastric non-cardia adenocarcinoma were identified, and 10 000 control persons were randomly sampled.
  • "Oesophageal" indication for long term acid suppression (that is, reflux symptoms, oesophagitis, Barrett's oesophagus, or hiatal hernia) rendered a fivefold increased risk of oesophageal adenocarcinoma (odds ratio (OR) 5.42 (95% confidence interval (CI) 3.13-9.39)) while no association was observed among users with a group of other indications, including peptic ulcer and "gastroduodenal symptoms" (that is, gastritis, dyspepsia, indigestion, and epigastric pain) (OR 1.74 (95% CI 0.90-3.34)).
  • "Peptic ulcer" indication (that is, gastric ulcer, duodenal ulcer, or unspecified peptic ulcer) was associated with a greater than fourfold increased risk of gastric non-cardia adenocarcinoma among long term users (OR 4.66 (95% CI 2.42-8.97)) but no such association was found in those treated for a group of other indications (that is, "oesophageal" or "gastroduodenal symptoms") (OR 1.18 (95% CI 0.60-2.32)).
  • CONCLUSIONS: Long term pharmacological gastric acid suppression is a marker of increased risk of oesophageal and gastric adenocarcinoma.
  • However, these associations are most likely explained by the underlying treatment indication being a risk factor for the cancer rather than an independent harmful effect of these agents per se.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antacids / adverse effects. Esophageal Neoplasms / chemically induced. Stomach Neoplasms / chemically induced


51. Cui M, Yu W, Dong J, Chen J, Zhang X, Liu Y: Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma. Med Oncol; 2010 Sep;27(3):632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma.
  • The expression of ABI1 and its role in cancer progression and prognosis are largely unknown in the majority of solid tumors, including gastric cancer.
  • In this study, we analyzed the correlation between ABI1 expression and the clinicopathological characteristics, tumor progression, and prognosis of patients with gastric carcinoma.
  • Tissue specimens were from 103 gastric cancer patients who underwent gastrectomy in our hospital between January 2000 and December 2007.
  • Meanwhile, quantitative real-time RT-PCR and Western blotting were used to identify the expression of ABI1 in human gastric normal mucosal cell line (GES-1) and gastric cancer cell lines (N87, AGS).
  • The immunohistochemical staining results of 59 patients showed that ABI1 was expressed in 28.8% (17/59) of gastric cancer tissues, compared to 91.5% (54/59) of normal samples.
  • Downregulation of ABI1 expression in human gastric carcinoma may play a critical role in tumor progression and in determining patient prognosis.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Adenocarcinoma / genetics. Cytoskeletal Proteins / physiology. Neoplasm Proteins / physiology. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1994 Jan;16(1):7-10 [8033753.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1405-8 [12390382.001]
  • [Cites] Orv Hetil. 2005 Jun 12;146(24):1293-9 [16025998.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1669-77 [18347167.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):461-9 [15691647.001]
  • [Cites] Genes Dev. 1998 May 15;12(10):1415-24 [9585502.001]
  • [Cites] FEBS Lett. 2003 Apr 10;540(1-3):195-200 [12681507.001]
  • [Cites] Cell. 2003 Feb 21;112(4):453-65 [12600310.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):51-56 [11957043.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Jun;4(4):345-54 [15180500.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1717-24 [18453543.001]
  • [Cites] BMC Cancer. 2008 Jan 28;8:25 [18226209.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5237-44 [15289329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1098-103 [15657136.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Oncologist. 2006 Feb;11(2):136-45 [16476834.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31290-7 [16899465.001]
  • [Cites] Exp Cell Res. 2005 Nov 1;310(2):463-73 [16182283.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2583-97 [7590237.001]
  • [Cites] Mol Cancer Res. 2007 Oct;5(10):1031-9 [17951403.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4926-34 [11526477.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):233-41 [9010225.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):4-10 [16343889.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28954-60 [11387320.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7591-601 [11003655.001]
  • [Cites] Neoplasia. 2001 Mar-Apr;3(2):99-104 [11420744.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):57-9 [12547160.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 19554484.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABI1 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


52. Sitarz R, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ, Milne AN: The COX-2 promoter polymorphism -765 G&gt;C is associated with early-onset, conventional and stump gastric cancers. Mod Pathol; 2008 Jun;21(6):685-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers.
  • COX-2 overexpression is known to be an important mechanism in gastric carcinogenesis.
  • Previously we have found that early-onset gastric cancer has a unique COX-2 low-expressing phenotype that differs significantly from that of the frequent overexpression seen in conventional gastric cancers.
  • To investigate whether the COX-2 -765 G>C promoter polymorphism (known to lead to a reduction of COX-2 promoter activity in the colon) may explain this difference in expression, we carried out single-nucleotide polymorphism (SNP) analysis of 241 gastric cancers, including early-onset gastric cancer, conventional gastric cancers and gastric stump cancers, as well as in 100 control patients, using real-time PCR and sequence analysis, and correlated these findings with COX-2 expression using immunohistochemistry.
  • We found that the C allele was present in 30% of early-onset gastric cancers, 24% of conventional gastric cancer, 23% of stump cancers, in contrast to 41% in the control group.
  • There was a statistically significant difference in the presence of the C allele in patients with gastric cancer compared with the control group (P=0.007), with the C allele being associated with protection against gastric cancer.
  • However, there was no significant difference between the early-onset, conventional and stump gastric cancer groups.
  • In summary, we show that the COX-2 -765 G allele promoter polymorphism is significantly associated with gastric cancer when compared with the normal control group, but does not appear to be related directly to COX-2 expression pattern in gastric cancer.
  • Although early-onset gastric cancers appear to have a unique COX-2 expression pattern when compared with conventional gastric cancer, the exact mechanism by which this occurs is yet to be elucidated.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclooxygenase 2 / genetics. Genetic Predisposition to Disease. Promoter Regions, Genetic / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311113.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


53. Cioppa T, Marrelli D, Neri A, Caruso S, Pedrazzani C, Malagnino V, Pinto E, Roviello F: A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy. Eur J Cancer Care (Engl); 2007 Sep;16(5):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy.
  • Primary small-cell carcinoma (SmCC) of the stomach is a rare neoplasm with a poor prognosis and unclear histogenesis: to date, only 50 cases, including ours, have been reported in the literature.
  • In the World Health Organization gastrointestinal tumours' classification, SmCC of the stomach has been recognized as an 'independent entity affecting the stomach'.
  • In this paper, the authors present a clinical case and the surgical treatment of an adult with a SmCC of the stomach associated with gastric adenocarcinoma.
  • A review of the literature showed that the diagnosis of gastric SmCC is based on immunohistochemical findings.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / secondary. Kidney Neoplasms / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17760934.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Kodera Y, Ito S, Mochizuki Y, Kondo K, Koshikawa K, Suzuki N, Kojima H, Kojima T, Matsui T, Takase T, Tsuboi K, Fujiwara M, Nakao A, Chubu Clinical Oncology Group: A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol; 2009 Nov;35(11):1158-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study).
  • BACKGROUND: Patients with gastric cancer who have positive cytologic results for cancer cells in peritoneal washings (CY1) have poor outcomes, even in the absence of other distant metastases.
  • Patients who had gastric cancer with CY1 status but no other residual disease received postoperative chemotherapy with S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) at a daily dose of 80mg/m(2) for 4 weeks, followed by 2 weeks of rest.
  • CONCLUSIONS: Gastrectomy followed by S-1 monotherapy resulted in survival that surpassed historical data and can serve as an active control treatment for future trials in patients who have gastric cancer with CY1 status in the Far East.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy / methods. Peritoneal Cavity / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328643.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


55. Saadat M: Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis. Cancer Sci; 2006 Jun;97(6):505-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of glutathione S-transferase T1 (GSTT1) and susceptibility to gastric cancer: a meta-analysis.
  • The association between glutathione S-transferase T1 (GSTT1) polymorphism and gastric cancer risk has been both confirmed and refuted in a number of published studies.
  • We carried out a meta-analysis of the research published up to August 2005 to obtain more precise estimates of gastric cancer risk associated with GSTT1 polymorphism.
  • The GSTT1 null genotype conferred a 1.06-fold increased risk of gastric cancer, which was not significant (95% confidence interval [CI]: 0.94-1.19).
  • To investigate whether the profile of glutathione S-transferase genotypes was associated with risk of gastric cancer, further analyses combining the GSTT1 and GSTM1 genotypes were also carried out.
  • Those who had null genotypes of GSTM1 and GSTT1 had an increased gastric cancer risk compared with those who had both active genes (odds ratio = 2.08, 95% CI: 1.42-3.10).
  • [MeSH-major] Adenocarcinoma / genetics. Genetic Predisposition to Disease. Glutathione Transferase / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734729.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


56. Goto Y, Ando T, Nishio K, Kawai S, Ishida Y, Naito M, Goto H, Hamajima N: Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy. Int J Med Sci; 2007;4(1):1-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grb2-associated binder 1 polymorphism was associated with the risk of Helicobactor pylori infection and gastric atrophy.
  • BACKGROUND: Various single nucleotide polymorphisms (SNPs) have explained the association between Helicobacter pylori (H. pylori) and gastric atrophy and cancer.
  • This study investigated the associations of Grb2 associated binder 1 (Gab1) polymorphism and the combination of PTPN11 gene encoding src homology 2 domain-containing protein tyrosine phosphatase-2 (SHP2) and Gab1 gene with gastric cancer and gastric atrophy among H. pylori seropositive subjects.
  • METHODS: A single nucleotide polymorphism at intron 2 of Gab1 (JST164345) was examined for 454 Japanese health checkup examinees (126 males and 328 females) aged 35 to 85 without a history of gastric cancer and 202 gastric cancer patients (134 males and 68 females) aged 33 to 94 with pathologically confirmed diagnosis of gastric adenocarcinoma.
  • Among seropositive healthy controls, the OR of the Gab1 G/A+A/A for gastric atrophy was significant (OR=1.95, 95% CI: 1.12 -3.40).
  • Seropositive individuals with PTPN11 G/G and Gab1 G/A+A/A demonstrated the highest risk of gastric atrophy with significance (OR=3.49, 95% CI: 1.54-7.90) relative to PTPN11 G/A+A/A and Gab1 G/G, the lowest risk combination, as a reference.
  • Compared to gastric cancer case, the Gab1 did not influence the step of atrophy/metaplasia-gastric cancer sequence.
  • CONCLUSIONS: This study represents that the Gab1 polymorphism was associated with the low risk of H. pylori infection and the high risk of gastric atrophy among seropositive healthy controls, and that seropositive individuals with PTPN11 G/G and Gab1 G/A+G/G were associated with the greatest risk of gastric atrophy.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Gastric Mucosa / pathology. Helicobacter Infections / etiology. Helicobacter pylori. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Atrophy. Female. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Male. Metaplasia. Middle Aged. Odds Ratio. Protein Phosphatase 2. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatases / genetics. Protein Tyrosine Phosphatases / metabolism. Risk Factors. SH2 Domain-Containing Protein Tyrosine Phosphatases. Stomach Neoplasms / etiology. src Homology Domains

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2000 Apr;37(3-4):299-307 [10752981.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13842-8 [10788507.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] J Clin Pathol. 2001 Sep;54(9):703-6 [11533078.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):24380-7 [11323411.001]
  • [Cites] Jpn J Cancer Res. 2001 Apr;92(4):383-9 [11346459.001]
  • [Cites] Jpn J Cancer Res. 2000 Sep;91(9):865-8 [11011111.001]
  • [Cites] Mol Cell Biol. 2000 Nov;20(22):8513-25 [11046147.001]
  • [Cites] J Cell Biol. 2000 Jun 26;149(7):1419-32 [10871282.001]
  • [Cites] Helicobacter. 2001 Dec;6(4):294-9 [11843961.001]
  • [Cites] FEBS Lett. 2002 Mar 27;515(1-3):1-7 [11943184.001]
  • [Cites] Int J Mol Med. 2002 Sep;10(3):321-6 [12165808.001]
  • [Cites] Oncogene. 2003 Mar 13;22(10):1546-56 [12629518.001]
  • [Cites] Microbes Infect. 2003 Feb;5(2):143-50 [12650772.001]
  • [Cites] Mol Biol Cell. 2003 Apr;14(4):1691-708 [12686619.001]
  • [Cites] Gastric Cancer. 2003;6(4):230-6 [14716517.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2007-15 [15026337.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] Lancet. 1975 Jul 12;2(7924):58-60 [49653.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):203-8 [16032704.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1809-16 [10068651.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16643-6 [9642214.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):1189-202 [8622663.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1611-4 [7681217.001]
  • [Cites] Science. 1993 Mar 12;259(5101):1607-11 [8096088.001]
  • (PMID = 17211494.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GAB1 protein, human; 0 / Intracellular Signaling Peptides and Proteins; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / SH2 Domain-Containing Protein Tyrosine Phosphatases
  • [Other-IDs] NLM/ PMC1752235
  •  go-up   go-down


57. Salinas Martín MV, Carranza Carranza A, Gavilán Carrasco F: [Diffuse gastric carcinoma associated with localized Ménétrier's disease]. Med Clin (Barc); 2008 Feb 23;130(6):239
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diffuse gastric carcinoma associated with localized Ménétrier's disease].
  • [Transliterated title] Carcinoma gástrico de tipo difuso asociado a enfermedad de Ménétrier localizada. Estudio clinicopatológico de dos casos.
  • [MeSH-major] Adenocarcinoma / complications. Gastritis, Hypertrophic / complications. Stomach Diseases / complications

  • MedlinePlus Health Information. consumer health - Stomach Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18346420.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Spain
  •  go-up   go-down


58. Zhang Y, Liu Y, Lu N, Shan NN, Zheng GX, Zhao SM, Zou X, Gao YJ, Li YJ, Wang YS: Expression of the genes encoding human leucocyte antigens-A, -B, -DP, -DQ and -G in gastric cancer patients. J Int Med Res; 2010 May-Jun;38(3):949-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the genes encoding human leucocyte antigens-A, -B, -DP, -DQ and -G in gastric cancer patients.
  • This study compared the expression of the genes encoding human leucocyte antigens (HLA)-A, -B, -DP, -DR and -G in peripheral blood mononuclear cells (PBMCs) in gastric cancer patients and healthy controls.
  • Using reverse transcription-polymerase chain reaction, levels of classical HLA-A, -B, -DP and -DR and non-classical HLA-G mRNA were studied in 43 gastric cancer patients and 22 controls.
  • In addition, the levels of HLA-A,B,C and -G antigens on the surface of PBMCs were measured in 30 gastric cancer patients and 15 controls using flow cytometry.
  • The mean fluorescence intensity of HLA-A,B,C antigen in the gastric cancer group was significantly lower than in controls.
  • The percentage of CD4(+)CD8(-) T-lymphocytes positive for HLA-G antigen was significantly lower in the gastric cancer group compared with the healthy controls.
  • Levels of HLA-A, -B and -G mRNA in the gastric cancer group were significantly lower than in controls.
  • The HLA-G mRNA levels were significantly lower in gastric cancer of histological grades III and IV than in grades I and II.
  • These data may provide a novel diagnostic and research tool for gastric cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Gene Expression. HLA Antigens / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819431.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / RNA, Messenger
  •  go-up   go-down


59. Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E, Bepler G: Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer; 2008 Jun 15;112(12):2765-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.
  • TS messenger RNA and protein levels are predictive of response to 5-fluorouracil-containing therapy for patients with colorectal cancer and gastric cancer.
  • High levels of expression of 2 other genes important in DNA synthesis and repair, RRM1 and ERCC1, are prognostic of survival in early stage nonsmall-cell lung cancer (NSCLC) patients.
  • [MeSH-minor] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Carcinoma, Large Cell / metabolism. DNA-Binding Proteins / metabolism. Endonucleases / metabolism. Female. Humans. Male. Neoplasms, Squamous Cell / metabolism. Prognosis. RNA, Messenger / metabolism. Smoking. Survival Analysis. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • [Cites] J Clin Oncol. 2001 Dec 1;19(23):4298-304 [11731512.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):488-92 [10690528.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Oncogene. 2003 Apr 10;22(14):2135-42 [12687015.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1878-85 [15143080.001]
  • [Cites] Mol Pharmacol. 1984 Jan;25(1):171-7 [6708932.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1328-33 [7882331.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Stat Med. 1996 Jan 15;15(1):103-12 [8614741.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] Chest. 2005 Mar;127(3):978-83 [15764785.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6497-502 [16818620.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):914-6 [16900128.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1589-96 [16955506.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):800-8 [17314339.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):304-13 [12096112.001]
  • (PMID = 18442042.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102726; United States / NCI NIH HHS / CA / R01 CA102726
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RRM1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.1.1.45 / Thymidylate Synthase; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases
  • [Other-IDs] NLM/ NIHMS530227; NLM/ PMC3857609
  •  go-up   go-down


60. Ishikawa M, Kitayama J, Fujii S, Ishigami H, Kaizaki S, Nagawa H: Recurrent intramucosal gastric carcinoma with extensive invasion to duodenal mucosa after endoscopic mucosal resection: a case report. Am Surg; 2005 Apr;71(4):366-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent intramucosal gastric carcinoma with extensive invasion to duodenal mucosa after endoscopic mucosal resection: a case report.
  • The occurrence of early gastric carcinoma with invasion to the duodenum is supposed to be very low, although advanced cancers arising in the antrum can often invade the duodenal area.
  • Generally, malignant invasion of the duodenum is difficult to diagnose preoperatively, as spread of gastric cancer to the duodenum is often infiltrative and invades through the submucosal or subserosal layer.
  • We report an unusual case of an intramucosal gastric carcinoma with extensive duodenal invasion that was preoperatively diagnosed by endoscopy.
  • [MeSH-major] Adenocarcinoma / pathology. Duodenal Neoplasms / pathology. Endoscopy, Gastrointestinal. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Follow-Up Studies. Gastrectomy. Gastric Mucosa / pathology. Humans. Laser Coagulation. Male. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943416.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Crew KD, Neugut AI: Epidemiology of gastric cancer. World J Gastroenterol; 2006 Jan 21;12(3):354-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of gastric cancer.
  • The incidence and mortality of gastric cancer have fallen dramatically in US and elsewhere over the past several decades.
  • Nonetheless, gastric cancer remains a major public health issue as the fourth most common cancer and the second leading cause of cancer death worldwide.
  • While there has been a marked decline in distal, intestinal type gastric cancers, the incidence of proximal, diffuse type adenocarcinomas of the gastric cardia has been increasing, particularly in the Western countries.
  • Distal gastric cancer predominates in developing countries, among blacks, and in lower socio-economic groups, whereas proximal tumors are more common in developed countries, among whites, and in higher socio-economic classes.
  • Diverging trends in the incidence of gastric cancer by tumor location suggest that they may represent two diseases with different etiologies.
  • The main risk factors for distal gastric cancer include Helicobacter pylori (H pylori) infection and dietary factors, whereas gastroesophageal reflux disease and obesity play important roles in the development of proximal stomach cancer.
  • The purpose of this review is to examine the epidemiology and risk factors of gastric cancer, and to discuss strategies for primary prevention.
  • [MeSH-major] Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):531-5 [11802218.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):35-41 [11815399.001]
  • [Cites] Gut. 2002 Mar;50(3):368-72 [11839716.001]
  • [Cites] World J Gastroenterol. 2001 Aug;7(4):563-5 [11819830.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):309-13 [12177800.001]
  • [Cites] Int J Cancer. 2002 Oct 1;101(4):380-9 [12209964.001]
  • [Cites] Int J Cancer. 2002 Nov 1;102(1):39-44 [12353232.001]
  • [Cites] N Engl J Med. 2002 Oct 10;347(15):1175-86 [12374879.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] J Infect Dis. 2002 Dec 1;186(11):1621-30 [12447739.001]
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):2992-7 [12492181.001]
  • [Cites] World J Gastroenterol. 2003 Mar;9(3):432-6 [12632491.001]
  • [Cites] BMJ. 2003 Apr 5;326(7392):737 [12676842.001]
  • [Cites] N Engl J Med. 2003 Apr 24;348(17):1625-38 [12711737.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1193-201 [12730860.001]
  • [Cites] J Epidemiol. 2003 May;13(3):162-8 [12749604.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jul;128(7):765-70 [15214826.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6329-40 [15322508.001]
  • [Cites] Int J Epidemiol. 2004 Aug;33(4):808-15 [15020567.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):1049-55 [15386347.001]
  • [Cites] Int J Cancer. 1968 Nov 15;3(6):809-18 [5731983.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1449-59 [4762929.001]
  • [Cites] J Natl Cancer Inst. 1975 Jul;55(1):101-6 [808633.001]
  • [Cites] Int J Cancer. 1980 Apr 15;25(4):431-7 [7372370.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1311-5 [6145023.001]
  • [Cites] Epidemiol Rev. 1986;8:1-27 [3533579.001]
  • [Cites] Princess Takamatsu Symp. 1985;16:169-82 [3916194.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):265-9 [1467772.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):271-4 [1467773.001]
  • [Cites] Environ Health Perspect. 1992 Nov;98:207-10 [1486851.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):745-50 [8431855.001]
  • [Cites] Lancet. 1993 May 29;341(8857):1359-62 [8098787.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):594-606 [8514451.001]
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1483-92 [8360931.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jan-Feb;3(1):15-8 [8118379.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] BMJ. 1994 Mar 19;308(6931):750-3 [8142828.001]
  • [Cites] Int J Cancer. 1994 Jun 1;57(5):638-44 [8194870.001]
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):393-8 [7920206.001]
  • [Cites] Am J Gastroenterol. 1994 Oct;89(10):1806-10 [7942672.001]
  • [Cites] J Clin Pathol. 1994 Aug;47(8):695-8 [7962618.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Oct-Nov;3(7):607-11 [7827592.001]
  • [Cites] Int J Cancer. 1995 Mar 3;60(5):642-4 [7860138.001]
  • [Cites] Dig Dis. 1994 Sep-Oct;12(5):276-89 [7882548.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2789-93 [7773928.001]
  • [Cites] Aliment Pharmacol Ther. 1995;9 Suppl 2:45-51 [8547528.001]
  • [Cites] Scand J Gastroenterol. 1996 Jul;31(7):643-7 [8819211.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):41-55 [8850434.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Sep;5(9):673-7 [8877056.001]
  • [Cites] Int J Epidemiol. 1996 Oct;25(5):941-7 [8921478.001]
  • [Cites] J Korean Med Sci. 1996 Oct;11(5):373-85 [8934391.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Carcinogenesis. 1997 Apr;18(4):795-9 [9111217.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):340-4 [9139864.001]
  • [Cites] J Clin Microbiol. 1997 Jul;35(7):1710-4 [9196179.001]
  • [Cites] J Gastroenterol. 1997 Jun;32(3):289-94 [9213239.001]
  • [Cites] Lab Invest. 1999 Dec;79(12):1469-77 [10616198.001]
  • [Cites] IARC Sci Publ. 1999;(151):1-572 [10619122.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Jan;14(1):45-51 [10632644.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):101-5 [10638566.001]
  • [Cites] Lancet. 2000 Jan 29;355(9201):358-62 [10665555.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):119-23 [10667472.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] Nature. 2000 Mar 23;404(6776):398-402 [10746728.001]
  • [Cites] J Clin Gastroenterol. 2000 Jul;31(1):33-7 [10914773.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):601-6 [11058877.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1883-92 [11064344.001]
  • [Cites] Scand J Gastroenterol. 2000 Oct;35(10):1023-32 [11099054.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1881-8 [11106679.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Dec;15(12):1382-5 [11197047.001]
  • [Cites] N Engl J Med. 2001 Mar 1;344(9):632-6 [11228277.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):400-5 [11161407.001]
  • [Cites] Helicobacter. 2000 Dec;5(4):202-5 [11179984.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Mar;15(3):379-88 [11207513.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):965-8 [11286478.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):600-4 [11304697.001]
  • [Cites] Gut. 2001 Sep;49(3):330-4 [11511552.001]
  • [Cites] Gut. 2001 Sep;49(3):341-6 [11511554.001]
  • [Cites] Gut. 2001 Sep;49(3):347-53 [11511555.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):501-8 [11519758.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):471 [11689605.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1201-5 [11700269.001]
  • [Cites] Dig Liver Dis. 2001 Nov;33(8):665-70 [11785711.001]
  • [Cites] Int J Epidemiol. 1998 Apr;27(2):173-80 [9602395.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1998 May;10(5):375-9 [9619382.001]
  • [Cites] Gastroenterology. 1998 Jul;115(1):50-7 [9649458.001]
  • [Cites] Nature. 1999 Jan 14;397(6715):176-80 [9923682.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2167-75 [10070283.001]
  • [Cites] J Infect Dis. 1999 Jun;179(6):1523-30 [10228075.001]
  • [Cites] Am J Gastroenterol. 1999 May;94(5):1218-23 [10235197.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] Jpn J Cancer Res. 1995 Oct;86(10):916-23 [7493909.001]
  • [Cites] Cancer Causes Control. 1995 Nov;6(6):532-8 [8580302.001]
  • [Cites] Aust N Z J Surg. 1996 May;66(5):271-5 [8634040.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2449-57 [8640692.001]
  • [Cites] Int J Epidemiol. 1996 Jun;25(3):494-504 [8671549.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):477-81 [8781746.001]
  • [Cites] Nature. 1997 Aug 7;388(6642):539-47 [9252185.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):565-73 [9259392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):639-42 [9264278.001]
  • [Cites] Gut. 1997 Sep;41(3):277-80 [9378377.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):837-9 [9399662.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):588-90 [9485003.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Scand J Gastroenterol. 1998 Mar;33(3):294-300 [9548624.001]
  • [Cites] Cancer Causes Control. 1998 Mar;9(2):209-16 [9578298.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Jun 15;17(12):1529-34 [12823156.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):629-34 [14520702.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1784-91 [14652240.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):128-34 [14710219.001]
  • [Cites] JAMA. 2004 Jan 14;291(2):187-94 [14722144.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):737-41 [14999783.001]
  • [Cites] Am J Epidemiol. 1999 May 15;149(10):925-32 [10342801.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1319-29 [10348815.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):353-60 [10365894.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Gut. 1999 Aug;45(2):181-5 [10403728.001]
  • [Cites] Eur J Cancer Prev. 1999 Jul;8(3):223-7 [10443951.001]
  • [Cites] Biomed Pharmacother. 1999 Aug;53(7):315-8 [10472431.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4823-8 [10519391.001]
  • [Cites] Br Med J. 1953 Apr 11;1(4814):799-801 [13032504.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1772-80 [15533906.001]
  • [Cites] Gut. 1989 Apr;30(4):436-42 [2714677.001]
  • [Cites] Mutat Res. 1989 Jul;223(3):273-85 [2500594.001]
  • [Cites] N Engl J Med. 1989 Dec 7;321(23):1562-6 [2586553.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):627-31 [2297702.001]
  • [Cites] Tumori. 1990 Apr 30;76(2):167-71 [2330608.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):896-901 [2335393.001]
  • [Cites] Br J Cancer. 1990 Jul;62(1):136-7 [2390474.001]
  • [Cites] Arch Intern Med. 1990 Oct;150(10):2022-6 [2222087.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):672-8 [2065291.001]
  • [Cites] J Korean Med Sci. 1991 Mar;6(1):7-14 [1888453.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1132-6 [1891021.001]
  • [Cites] Gastroenterology. 1992 Mar;102(3):760-6 [1537513.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1943-7 [1551122.001]
  • [Cites] J Clin Pathol. 1992 Apr;45(4):319-23 [1577969.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):50-5 [1606546.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):3875-9 [1617663.001]
  • [Cites] Jpn J Cancer Res. 1992 Jun;83(6):568-75 [1644660.001]
  • [Cites] Scand J Gastroenterol. 1992 May;27(5):362-6 [1529269.001]
  • [Cites] Eur J Cancer Prev. 1992 Feb;1(2):159-64 [1463978.001]
  • (PMID = 16489633.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 169
  • [Other-IDs] NLM/ PMC4066052
  •  go-up   go-down


62. Lagergren J: Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract Res Clin Gastroenterol; 2006;20(5):803-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis?
  • The rapid increase in the incidence of oesophageal adenocarcinoma, particularly among white males, seems to be a true increase occurring in many parts of the industrialised world during the last few decades.
  • Other factors have been found to be possibly inversely linked with the risk of oesophageal adenocarcinoma, including infection with Helicobacter pylori and anti-inflammatory drugs (such as aspirin and other non-steroidal anti-inflammatory drugs, including cyclo-oxygenase inhibitors).
  • The methodological problem of 'confounding by indication' makes it difficult to interpret the results of anti-inflammatory drugs, and currently such medication cannot be recommended for the prevention of oesophageal adenocarcinoma.
  • Similarly, since there is no strong evidence of a preventive effect of medical or surgical antireflux therapy with regard to risk of oesophageal adenocarcinoma, such therapy cannot be recommended in the prevention of this cancer.
  • Although some of the known risk factors might contribute to the increasing incidence of oesophageal adenocarcinoma, the explanation that can entirely explain this striking trend remains to be identified.
  • Oesophageal adenocarcinoma is a highly deadly cancer, but the overall prognosis and the prognosis after oesophageal cancer surgery has improved during recent years.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / prevention & control. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997162.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Number-of-references] 69
  •  go-up   go-down


63. Ozdemir NY, Abali H, Oksüzoğlu B, Budakoglu B, Uncu D, Güler T, Odabaşi H, Zengin N: The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. Med Oncol; 2010 Sep;27(3):680-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
  • Patients with advanced gastric carcinoma have still had bad prognosis despite advances in the modern treatment era.
  • From July 2005 to July 2008, 37 advanced gastric cancer patients treated with at least one course of mDCF protocol as first-line treatment were included.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Jun;15(6):955-9 [15151954.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2903-9 [16782930.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3217-23 [17664469.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):536-40 [1548518.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):587-91 [7533517.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):641-6 [11857295.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3721-8 [12963704.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):37-41 [8508427.001]
  • [Cites] JAMA. 1985 Apr 12;253(14):2061-7 [2579257.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1310-7 [2671287.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • (PMID = 19633962.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


64. Sakamoto K, Koshiishi H, Kakimoto M, Nishida K, Masuda T, Chika N, Hosokawa T, Matsuyama T, Tokita H, Goto H, Yoshimura T, Okamura T, Dan N, Kato H, Mitsuhashi Y: [A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2795-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy].
  • Cancerous pleural effusion and gastric cancer was diagnosed, and the chemotherapy consisted of S-1 + DOC was started for Stage IV gastric cancer.
  • In 2009, lung cancer was found.
  • This chemotherapy was effective for both lung and gastric cancers.
  • Operation was performed for both tumors in 2010, and the pathological diagnosis revealed that gastric cancer was pStage I, Cur A, and the lung cancer was pStage IA, R0.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Neoadjuvant Therapy. Neoplasms, Multiple Primary / drug therapy. Stomach Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Taxoids; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


65. Lee SY, Hwang I, Park YS, Gardner J, Ro JY: Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes? Int J Oncol; 2010 Jun;36(6):1461-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lymph node ratio in advanced gastric carcinoma: a better prognostic factor than number of metastatic lymph nodes?
  • Gastric carcinoma is the most common cancer and the second most common cause of cancer-related death in Korea.
  • Among the category I prognostic factors of gastric carcinoma, lymph node metastasis (nodal status) is considered to be the strongest prognostic factor.
  • According to the current UICC (the International Union Against Cancer)/AJCC (American Joint Committee on Cancer) staging system, nodal status is categorized based on the number of metastatic lymph nodes (pN0, no metastasis; pN1, 1-6 lymph nodes positive; pN2, 7-15 and pN3, >15).
  • In the present study, we aimed to evaluate which lymph node assessment method, metastatic lymph node number vs. ratio of metastasis, was better to predict survival in comparison with known prognostic factors in advanced gastric carcinoma in Korea.
  • Based on our study, we demonstrate that the MLR was a simple and reproducible prognostic factor that supplemented the limitation of the conventional N staging system, and provided more accurate prognostic stratification in advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Metastasis / pathology. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428770.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


66. Wang JH, Huang WS, Hu CR, Guan XX, Zhou HB, Chen LB: Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma. World J Gastroenterol; 2010 Nov 28;16(44):5642-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma.
  • AIM: To explore the regulator of G-protein signaling 5 (RGS5) expression in gastric carcinoma and its association with differentiation and microvascular density (MVD).
  • METHODS: Expression of RGS5 and CD34 were examined in 76 cases of gastric carcinoma, including 22 cases with lymph node metastasis and 54 cases without lymph node metastasis determined by immunohistochemistry (IHC).
  • RESULTS: The RGS5 expression in gastric carcinoma was positively correlated with the differentiation of the tumor (r = 0.345, P < 0.001), but not related with age, gender, tumor size, clinical stage and lymph node metastasis (P > 0.05).
  • CONCLUSION: RGS5 expression level in gastric carcinoma is associated with the differentiation and MVD of the tumor, and may be used as an important parameter for determining the prognosis of gastric carcinoma patients.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Microvessels / pathology. Neovascularization, Pathologic / pathology. RGS Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Pharmacol Toxicol. 2000;40:235-71 [10836135.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):396-9 [19147548.001]
  • [Cites] Cell Signal. 2002 Jul;14(7):595-606 [11955952.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):639-50 [12209124.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):721-9 [12598306.001]
  • [Cites] FASEB J. 2003 Mar;17(3):440-2 [12514120.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2322-9 [12727857.001]
  • [Cites] J Pathol. 2004 May;203(1):551-8 [15095478.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2406-8 [15175443.001]
  • [Cites] J Vasc Surg. 2004 Sep;40(3):519-28 [15337883.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1198-210 [15154008.001]
  • [Cites] J Immunol. 1995 Jun 1;154(11):5876-84 [7538536.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):553-63 [15607960.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1094-101 [15459006.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):870-9 [16113679.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):452-64 [16212810.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):299-309 [16226705.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3347-55 [17545542.001]
  • [Cites] Nat Med. 2008 Jan;14(1):28-36 [18157142.001]
  • [Cites] Cancer Cell. 2008 Mar;13(3):206-20 [18328425.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(7):2324-31 [18212066.001]
  • [Cites] Mol Cell Biol. 2008 Apr;28(8):2590-7 [18268011.001]
  • [Cites] Nature. 2008 May 15;453(7193):410-4 [18418378.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1126-32 [18546273.001]
  • [Cites] Cell Cycle. 2008 Aug 15;7(16):2452-5 [18719382.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1462-70 [11888921.001]
  • (PMID = 21105200.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / RGS Proteins; 0 / RGS5 protein, human
  • [Other-IDs] NLM/ PMC2992685
  •  go-up   go-down


67. Guglielmini C, Civitella C, Malatesta D, Palmieri C: Metastatic pericardial tumors in a dog with equivocal pericardial cytological findings. J Am Anim Hosp Assoc; 2007 Sep-Oct;43(5):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathological examination confirmed the diagnosis of multiple metastatic tumors of the pericardium, with the primary tumor being an anaplastic gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Heart Neoplasms / veterinary. Stomach Neoplasms / veterinary
  • [MeSH-minor] Animals. Dogs. Echocardiography / methods. Echocardiography / veterinary. Fatal Outcome. Female. Neoplasm Metastasis. Pericardial Effusion / diagnosis. Pericardial Effusion / etiology. Pericardial Effusion / veterinary. Pericardium / cytology. Pericardium / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823478.001).
  • [ISSN] 1547-3317
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H: Plasma adiponectin and gastric cancer. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):466-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma adiponectin and gastric cancer.
  • BACKGROUND: Recently, increased body weight has been associated with an increased risk of cancers at multiple specific sites, including gastric cancer.
  • METHODS: Fasting plasma levels of adiponectin were determined in 75 patients with gastric cancer and 52 healthy controls using an ELISA.
  • In these patients, we analyzed the association between plasma adiponectin level and gastric cancer risk as well as various clinicopathologic characteristics.
  • RESULTS: Plasma adiponectin level was significantly lower in patients with gastric cancer than in healthy controls (9.1 +/- 6.2 versus 13.3 +/- 9.4 ng/mL, P < 0.01) and showed a significant modest inverse relation with the gastric cancer (odds ratio, 0.92; 95% confidence interval, 0.85-0.97; adjusted odds ratio, 0.89; 95% confidence interval, 0.84-0.95], although body mass index was not different.
  • In addition, adiponectin level was extremely low in patients with upper gastric cancers (upper, 5.5 +/- 4.1 ng/mL; middle, 9.7 +/- 6.4 ng/mL; lower, 10.7 +/- 4.1 ng/mL; P = 0.012).
  • Interestingly, in 32 patients with undifferentiated cancer, serum adiponectin showed a negative correlation with pathologic findings such as tumor size, depth of invasion, as well as tumor stage (P < 0.05), but no correlation in the remaining 43 patients with differentiated cancer.
  • CONCLUSIONS: Our results suggest that a low plasma adiponectin level is associated with an increased risk for gastric cancer and raise the possibility that adiponectin has a potential role in the progression of gastric cancer, especially in undifferentiated type cancers in the upper stomach.
  • [MeSH-major] Intercellular Signaling Peptides and Proteins / blood. Stomach Neoplasms / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / etiology. Adiponectin. Body Mass Index. Carcinoma, Signet Ring Cell / blood. Carcinoma, Signet Ring Cell / etiology. Case-Control Studies. Cell Differentiation. Collagen / blood. Down-Regulation. Fasting. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Stomach / metabolism. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701829.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG 21418; United States / NCI NIH HHS / CA / R01 CA 1018447; United States / NIDDK NIH HHS / DK / T32 DK 07790
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Intercellular Signaling Peptides and Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


69. Sim HL, Tan KY, Poon PL, Cheng A: Primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries. World J Gastroenterol; 2008 Apr 7;14(13):2118-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rectal signet ring cell carcinoma with peritoneal dissemination and gastric secondaries.
  • Disseminated signet ring cell carcinomas frequently arise from the stomach.
  • Biopsy of the lesions revealed signet ring cell adenocarcinoma.
  • Gastroscopy showed multiple nodules with ulceration over several areas of the stomach which were similar in appearance to the colonic lesions.
  • However, no primary tumour of the stomach was seen.
  • Biopsy of the gastric lesions also showed signet ring cell adenocarcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Colonoscopy / methods. Peritoneum / pathology. Rectal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Female. Humans. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1975 May-Jun;18(4):332-8 [165050.001]
  • [Cites] Cancer. 2004 May 1;100(9):1776-85 [15112256.001]
  • [Cites] ANZ J Surg. 2001 Dec;71(12):703-6 [11906382.001]
  • [Cites] APMIS. 2000 Jun;108(6):467-72 [11028811.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):183-8 [10981869.001]
  • [Cites] Cancer. 1978 Jun;41(6):2420-5 [207410.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1453-7 [6311394.001]
  • [Cites] Cancer. 1985 Dec 1;56(11):2723-6 [2996745.001]
  • [Cites] Oncology. 1994 Jan-Feb;51(1):30-4 [8265100.001]
  • [Cites] Am J Gastroenterol. 1996 Oct;91(10):2195-9 [8855747.001]
  • [Cites] AMA Arch Surg. 1951 Jan;62(1):79-91 [14789350.001]
  • (PMID = 18395918.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2701538
  •  go-up   go-down


70. Dipetrillo T, Milas L, Evans D, Akerman P, Ng T, Miner T, Cruff D, Chauhan B, Iannitti D, Harrington D, Safran H: Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am J Clin Oncol; 2006 Aug;29(4):376-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study.
  • OBJECTIVES: To determine the maximal tolerated dose (MTD) and dose limiting toxicities of poly(l-glutamic acid)-paclitaxel (PPX) and concurrent radiation (PPX/RT) for patients with esophageal and gastric cancer.
  • METHODS: Patients with esophageal or gastric cancer receiving chemoradiation for loco-regional, adjuvant, or palliative intent were eligible.
  • Sixteen patients had esophageal cancer and 5 had gastric cancer.
  • CONCLUSIONS: The maximally tolerated dose of PPX with concurrent radiotherapy is 70 mg/m2/wk for patients with esophageal and gastric cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Paclitaxel / analogs & derivatives. Polyglutamic Acid / analogs & derivatives. Radiation-Sensitizing Agents / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Radiotherapy, Conformal

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891865.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiation-Sensitizing Agents; 0 / paclitaxel poliglumex; 25513-46-6 / Polyglutamic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


71. Maeda T, Kozakai N, Nishiyama T, Ishii T, Sugiura H, Nakamura K: [Gastric metastasis from renal cell carcinoma 20 months after radical nephrectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):137-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric metastasis from renal cell carcinoma 20 months after radical nephrectomy: a case report].
  • Metastatic lesions from renal cell carcinoma (RCC) commonly occur in the lung and bone, gastric metastasis has rarely been reported in the literature.
  • We present herein a case of a man with gastric metastasis from RCC.
  • Gastrointestinal endoscopy revealed a solitary polypoid lesion about 20 mm in diameter in the greater curvature of the middle gastric body.
  • Endoscopic needle biopsy revealed poorly differentiated adenocarcinoma.
  • Partial gastrectomy was performed and histologic examination of the resected specimen confirmed diagnosis of clear cell renal carcinoma.
  • Metastasis of any cancer to the stomach is quite uncommon.
  • In particular, gastric metastasis from RCC is extremely rare.
  • To our knowledge, this is the 15th case of gastric metastasis from RCC reported in Japan.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378824.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


72. Yoo NJ, Lee SH, Jeong EG, Lee SH: Expression of phosphorylated caspase-9 in gastric carcinomas. APMIS; 2007 Apr;115(4):354-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of phosphorylated caspase-9 in gastric carcinomas.
  • The aim of this study was to explore whether phosphorylated caspase-9 (p-caspase-9) expression could be a characteristic of gastric carcinomas.
  • We analyzed expression of p-caspase-9 protein in 60 gastric adenocarcinomas by immunohistochemistry using a tissue microarray approach. p-caspase-9 was detected in 33 of the 60 carcinomas (55%).
  • Both early and advanced gastric carcinomas expressed p-caspase-9.
  • In contrast to gastric cancer cells, epithelial cells in normal gastric mucosa showed no or only weak expression of p-caspase-9.
  • Taken together, these results indicate that caspase-9 is frequently phosphorylated in gastric carcinomas, and that the phosphorylation of caspase-9 might be an inhibitory mechanism of caspase-9-mediated apoptosis in gastric carcinomas.
  • Increased expression of p-caspase-9 in malignant gastric epithelial cells compared to normal mucosal epithelial cells suggests that p-caspase-9 expression might play a role in gastric carcinoma development.
  • [MeSH-major] Carcinoma / enzymology. Caspase 9 / analysis. Stomach Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504303.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 3.4.22.- / Caspase 9
  •  go-up   go-down


73. Yoshida S, Tanaka S, Hirata M, Mouri R, Kaneko I, Oka S, Yoshihara M, Chayama K: Optical biopsy of GI lesions by reflectance-type laser-scanning confocal microscopy. Gastrointest Endosc; 2007 Jul;66(1):144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-two areas of 15 untreated specimens from the esophagus (normal mucosa, n=1; dysplasia, n=1), stomach (normal mucosa, n=3; cancer, n=5), and colon (normal mucosa, n=3; adenoma, n=8; cancer, n=1) were examined.
  • Irregular nuclei were visualized in 3 of 5 gastric-cancer specimens and in cells around the crypt of the colonic-cancer specimen.
  • Nuclei were not visualized in 2 of 3 normal gastric-mucosa specimens or in normal colonic-mucosa specimens.
  • CONCLUSIONS: LCM provides instant microscopic images, and, with further technical improvement, in the future this novel method will aid in immediate diagnosis under endoscopy without the need for tissue biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Barrett Esophagus / pathology. Biopsy / methods. Colonic Neoplasms / pathology. Microscopy, Confocal. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2007 Jul;66(1):150-3 [17591489.001]
  • (PMID = 17591488.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Sicinschi LA, Lopez-Carrillo L, Camargo MC, Correa P, Sierra RA, Henry RR, Chen J, Zabaleta J, Piazuelo MB, Schneider BG: Gastric cancer risk in a Mexican population: role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin-1 and -10 genes. Int J Cancer; 2006 Feb 1;118(3):649-57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric cancer risk in a Mexican population: role of Helicobacter pylori CagA positive infection and polymorphisms in interleukin-1 and -10 genes.
  • Several polymorphisms of the IL1B and IL10 gene promoters have been reported to be associated with gastric cancer risk in Caucasians.
  • We aimed to test for associations between polymorphisms in IL1B (-31 and +3954), IL10-592 and IL1RN variable number of tandem repeats (VNTR) and risk of gastric cancer in a Mexican population.
  • DNA was extracted from sera of 183 gastric adenocarcinoma patients and 377 controls.
  • A significant interaction was found between IL1B-31 and CagA status for the risk of intestinal-type gastric cancer (p = 0.023).
  • Among CagA positive subjects, those with IL1B-31CC genotype had an increased risk of intestinal-type gastric cancer (OR 3.19, 95%CI = 1.05-9.68), compared to carriers of IL1B-31TT genotype.
  • In contrast, among CagA negative subjects, no significant association of IL1B-31CC genotype with gastric cancer was observed.
  • The IL10-592CC genotype was associated with more than doubling of the risk of the intestinal-type gastric cancer (OR, 2.20, 95%CI = 1.04-4.65).
  • A nonsignificantly increased risk for intestinal-type gastric cancer was found in IL1RN*2 carriers (OR 1.49, 95%CI = 0.89-2.50).
  • None of these polymorphisms was significantly related to the risk of diffuse-type gastric cancer.
  • No significant association was found between risk of gastric cancer and the IL1B+3954 polymorphism.
  • Individuals carrying 2 or more of the risk-associated alleles (IL1B-31C, IL1RN *2 and IL10-592C) were at increased risk for intestinal-type gastric cancer, compared to those with 0 or 1 risk-associated allele.
  • Our results support the identification of the IL1B-31 promoter polymorphism as a useful marker for risk of intestinal type gastric cancer in persons with CagA positive H. pylori infections.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Bacterial / immunology. Bacterial Proteins / immunology. Helicobacter Infections / genetics. Interleukin-1 / genetics. Interleukin-10 / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16114018.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 28842
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Interleukin-1; 0 / Receptors, Interleukin-1; 0 / cagA protein, Helicobacter pylori; 130068-27-8 / Interleukin-10
  •  go-up   go-down


75. Pesko P: Early complications following radical surgical treatment of patients with gastric adenocarcinoma. Vojnosanit Pregl; 2006 Mar;63(3):247-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early complications following radical surgical treatment of patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Postoperative Complications. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16605189.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] eng; srp
  • [Publication-type] Editorial
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


76. Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol; 2008 Nov;19(11):1882-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
  • BACKGROUND: The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity.
  • PATIENTS AND METHODS: Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669868.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Marcovechio Fonseca CA, Martinez JC, Piesciotto A, Yanagita ET, Denardin OV, Herani Filho B: Manometric study of the lower esophageal sphincter and esophagus in subtotal gastrectomy patients. Dis Esophagus; 2008;21(2):118-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied 26 patients with gastric adenocarcinoma of the distal corpus and/or antrum who underwent radical subtotal gastrectomy with Roux-en-Y reconstruction.
  • The authors suggest that subtotal gastrectomy, with gastroesophageal junction preservation, and Roux-en-Y reconstruction should be the preferred operation for distal gastric cancer to minimize esophageal dysfunction and gastroesophageal reflux disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269646.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Gerdes B, Ramaswamy A, Bartsch DK, Rothmund M: Peripyloric lymph node metastasis is a rare condition in carcinoma of the pancreatic head. Pancreas; 2005 Jul;31(1):88-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this prospective study was to identify the frequency of peripyloric and perigastric lymph node metastases in ductal adenocarcinoma of the pancreatic head (PC).
  • METHODS: Fifty specimens following Kausch-Whipple procedure including partial gastric resection for PC were analyzed for peripyloric and perigastric lymph node metastases by a standardized clearing technique.
  • Lymph nodes of the lesser and greater curvature of the stomach are not involved in patients with PC.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968254.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Wu WK, Tse TT, Sung JJ, Li ZJ, Yu L, Cho CH: Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res; 2009 Jan;29(1):229-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines.
  • BACKGROUND: ErbB receptors and their cognate ligands are implicated in cancer progression.
  • Their expression in gastrointestinal cancer, however, has not been systemically studied.
  • MATERIALS AND METHODS: The expression of four ErbB receptors and a panel of ErbB ligands were determined by reverse transcription-PCR in two gastric (TMK1, MKN-45) and two colon (SW1116, HT-29) cancer cell lines.
  • CONCLUSION: This study profiles the expression of ErbB receptors and their cognate ligands in gastric and colon cancer cells.
  • These findings might lay the basis for the development of ErbB pathway-directed therapeutics for gastrointestinal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Oncogene Proteins v-erbB / biosynthesis. Stomach Neoplasms / metabolism


80. Choi WH, Kim S, Shen J, Cheong JH, Hyung WJ, Kim YI, Choi SH, Noh SH, Park CI: Prognostic significance of perinodal extension in gastric cancer. J Surg Oncol; 2007 Jun 1;95(7):540-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of perinodal extension in gastric cancer.
  • METHODS: This study included a total of 1,092 patients who underwent curative gastrectomy for gastric adenocarcinoma from 1997 to 2004 at the Department of Surgery, Yongdong Severance Hospital, Yonsei University College of Medicine.
  • CONCLUSIONS: The perinodal extension was the most important independent prognostic factor in gastric cancer, and should be included in the TNM gastric cancer staging system.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Lymph Node Excision / mortality. Lymph Nodes / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17252555.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Shearer CJ, Going JJ, Neilson LJ, Stuart RC: Modified classification for adenocarcinoma of the gastro-oesophageal junction. ANZ J Surg; 2007 Jul;77(7):544-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified classification for adenocarcinoma of the gastro-oesophageal junction.
  • BACKGROUND: Incidence of the gastro-oesophageal junction adenocarcinoma is increasing.
  • Siewert's classification subdivides junctional adenocarcinomas anatomically.
  • Cytokeratin (CK) 7 and 20 immunophenotypes differentiate Barrett's intestinal metaplasia (IM) from gastric IM.
  • METHODS: In this experimental study, 57 patients with gastro-oesophageal junction adenocarcinoma were subdivided endoscopically into 15 type 1, 26 type 2 and 16 type 3 adenocarcinomas.
  • RESULTS: Intestinal metaplasia was associated with type 1 adenocarcinoma in 12 of 15 patients, 80%; with type 2 in 13 of 26 patients, 50% and type 3 in 6 of 16 patients, 37.5%.
  • All type 1 patients showed Barrett's CK7/CK20 phenotype within IM; type 2 a mixture: 69% (n=9) Barrett's CK7/CK20 and 31% (n=4) gastric CK7/CK20 whereas type 3 patients had a gastric CK7/CK20 pattern in 83% (n=5).
  • Immunostaining within the adenocarcinoma was variable.
  • CONCLUSION: Siewert's type 1 adenocarcinomas express Barrett's CK7/CK20 pattern, type 3 a gastric CK7/CK20 pattern and type 2 tumours a mixture of Barrett's and gastric CK7/CK20 patterns within associated IM.
  • CK immunostaining may refine Siewert's classification into oesophageal type 1 or gastric type 2 adenocarcinoma with IM.
  • [MeSH-major] Adenocarcinoma / classification. Esophageal Neoplasms / classification. Esophagogastric Junction

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610690.001).
  • [ISSN] 1445-1433
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


82. Batra M, Handa U, Mohan H, Sachdev A: Comparison of cytohistologic techniques in diagnosis of gastroesophageal malignancy. Acta Cytol; 2008 Jan-Feb;52(1):77-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cytohistologic techniques in diagnosis of gastroesophageal malignancy.
  • OBJECTIVE: To evaluate the diagnostic performance of various endoscopic cytologic techniques, namely, brushing cytology, touch smear cytology and crush cytology, and comparison with concurrent biopsy results in diagnosis of gastroesophageal malignancy.
  • STUDY DESIGN: This prospective study was conducted on 100 patients, with 78 clinically suspected cases of esophageal malignancy and 22 cases of gastric malignancy.
  • In comparison, the diagnostic accuracy in gastric malignancy was 75% for brushing alone, which was significantly lower than touch smear (87.5%) and endoscopic biopsy (87.5%).
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Biopsy / methods. Cytological Techniques / methods. Endoscopy, Gastrointestinal. Female. Gastroscopy / methods. Humans. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323279.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Comella P, Lorusso V, Maiorino L, Casaretti R, Cannone M, Massidda B, Putzu C, Leo S, Roselli M, Mancarella S, Palmeri S, Greco E, Vessia G, Sandomenico C, Franco L: Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group. Cancer Chemother Pharmacol; 2009 Oct;64(5):893-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
  • PURPOSE: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer.
  • METHODS: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m(2) iv and irinotecan 150 mg/m(2) iv on day 1, 6S-folinic acid 250 mg/m(2) iv and fluorouracil 750 mg/m(2) iv on day 2, every 2 weeks.
  • CONCLUSIONS: Oxaliplatin, irinotecan, and fluorouracil/folinic acid administered every 2 weeks are safe and active in advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19189106.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidotes; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


84. Watanabe K, Ogata S, Kawazoe S, Watanabe K, Koyama T, Kajiwara T, Shimoda Y, Takase Y, Irie K, Mizuguchi M, Tsunada S, Iwakiri R, Fujimoto K: Clinical outcomes of EMR for gastric tumors: historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection. Gastrointest Endosc; 2006 May;63(6):776-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of EMR for gastric tumors: historical pilot evaluation between endoscopic submucosal dissection and conventional mucosal resection.
  • BACKGROUND: EMR is currently a standard treatment for mucosal gastric tumors.
  • PATIENTS: EMR of 245 gastric tumors was performed in 229 patients.
  • [MeSH-major] Adenoma / surgery. Digestive System Surgical Procedures. Gastric Mucosa / surgery. Gastroscopy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Dissection / methods. Female. Humans. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16650537.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Razvi MH, Peng D, Dar AA, Powell SM, Frierson HF Jr, Moskaluk CA, Washington K, El-Rifai W: Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression. Genes Chromosomes Cancer; 2007 Oct;46(10):914-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression.
  • In our efforts to define gene expression alterations in Barrett's-related adenocarcinomas (BA), we produced eight SAGE libraries and obtained a total of 457,894 expressed tags with 32,035 (6.9%) accounting for singleton tags.
  • [MeSH-major] Adenocarcinoma / genetics. Barrett Esophagus / genetics. Biomarkers, Tumor / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Transcription, Genetic
  • [MeSH-minor] Antigens, CD13 / genetics. Antigens, CD13 / metabolism. Esophageal Neoplasms / genetics. Esophageal Neoplasms / metabolism. Expressed Sequence Tags. Female. Gastric Mucosa / metabolism. Gene Library. Humans. Immunoenzyme Techniques. Intestinal Neoplasms / genetics. Intestinal Neoplasms / metabolism. Male. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17636545.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 95103; United States / NCI NIH HHS / CA / R01CA106176
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


86. Labutina IuO: [Barrett's esophagus: contemporary diagnostic and therapeutic approaches]. Klin Med (Mosk); 2006;84(11):25-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Special attention is paid to the evaluation of BE as precancer elevating the risk of esophageal adenocarcinoma, as well as the issues of the treatment and regular medical check-up of such patients.
  • [MeSH-minor] Biopsy. Gastric Acidity Determination. Global Health. Humans. Incidence. Prognosis

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17243606.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histamine H2 Antagonists; 0 / Proton Pump Inhibitors
  • [Number-of-references] 39
  •  go-up   go-down


87. Phillips MS, Bonatti H, Adams RB, Kahaleh M: Aortoenteric fistula in a patient after pancreaticoduodenectomy and enteral stenting. Gastrointest Endosc; 2009 Sep;70(3):586-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Blood Vessel Prosthesis Implantation / methods. Gastric Outlet Obstruction / therapy. Intestinal Fistula / etiology. Pancreaticoduodenectomy / adverse effects. Stents / adverse effects. Vascular Fistula / etiology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aorta, Abdominal / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Staging. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Pancreaticojejunostomy / adverse effects. Pancreaticojejunostomy / methods. Postoperative Complications / radiography. Postoperative Complications / therapy. Reoperation. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19345352.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Orsenigo E, Tomajer V, Palo SD, Carlucci M, Vignali A, Tamburini A, Staudacher C: Impact of age on postoperative outcomes in 1118 gastric cancer patients undergoing surgical treatment. Gastric Cancer; 2007;10(1):39-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of age on postoperative outcomes in 1118 gastric cancer patients undergoing surgical treatment.
  • BACKGROUND: The purpose of the study was to evaluate the impact of age on outcomes in gastric cancer surgery.
  • METHODS: Patients on the hospital database who underwent gastric resection for gastric cancer during the period 1990-2005 (n = 1118) were divided into two groups: group A, patients 75 years or older (n = 249), and group B, those younger than 75 years (n = 869).
  • CONCLUSION: Due to improved perioperative management, resection of gastric carcinoma is the treatment of choice in elderly patients.
  • [MeSH-major] Adenocarcinoma / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):112-5 [9544826.001]
  • [Cites] Hepatogastroenterology. 1994 Dec;41(6):521-5 [7536703.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Surg Endosc. 2002 Mar;16(3):540-4 [11928051.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):206-15 [14710231.001]
  • [Cites] World J Surg. 2000 Apr;24(4):465-72 [10706921.001]
  • [Cites] J Clin Gastroenterol. 2001 Jan;32(1):3-4 [11154165.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] World J Surg. 2002 Sep;26(9):1145-9 [12209244.001]
  • [Cites] Surgery. 2003 Oct;134(4):720-7; discussion 727-9 [14605635.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):928-31 [7646924.001]
  • [Cites] J Clin Gastroenterol. 2002 Jul;35(1):29-34 [12080223.001]
  • [Cites] J Surg Res. 2004 May 1;118(1):15-20 [15093711.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):116-22 [9544827.001]
  • [Cites] Surg Oncol. 2004 Dec;13(4):235-8 [15615661.001]
  • (PMID = 17334717.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Clemons NJ, McColl KE, Fitzgerald RC: Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology; 2007 Oct;133(4):1198-209
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Transformed and primary Barrett's esophagus and adenocarcinoma cells were exposed to either acid, (pH 3.5), +/- antioxidant or NO from a donor or generated by acidification of nitrite in the presence of ascorbate +/- NO scavenger.
  • Exposure to physiologic concentrations of NO produced from the NO donor or acidification of salivary nitrite induced DSBs in a dose- (>25 micromol/L) and cell-dependent manner (adenocarcinoma >Barrett's esophagus, P < .05).
  • [MeSH-major] Adenocarcinoma / metabolism. Barrett Esophagus / complications. Cell Transformation, Neoplastic / metabolism. DNA Breaks, Single-Stranded. Esophageal Neoplasms / metabolism. Gastric Acid / metabolism. Nitric Oxide / metabolism


90. Mărgăritescu C, Mogoantă L, Mănescu P, Simionescu C, Pirici D, Streba L, Mercuţ D: The immunohistochemical profile of the adenocarcinoma of upper gastric pole. Rom J Morphol Embryol; 2007;48(3):215-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The immunohistochemical profile of the adenocarcinoma of upper gastric pole.
  • Although gastric adenocarcinoma continue to be the second continues to be the second cause of death worldwide, its incidence and mortality appear to have decreased in recent decades.
  • Despite this decline, adenocarcinomas from proximal stomach tend to be more frequent during the last three decade.
  • Adenocarcinomas with this location it seems that are a different, specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences between gastric adenocarcinomas from upper and distal gastric pole using the immunohistochemistry.
  • For this reason, we investigate histopathological and immunohistochemically 77 cases of upper gastric pole adenocarcinoma selected from a number of 472 gastric tumors.
  • The acquired results do not distinguish a peculiar immunohistochemically profile unlike distal gastric adenocarcinomas.
  • Nevertheless, we pointed out the predominance of diffuse adenocarcinomas type according to Laurens classification, which immunohistochemically were strong positive to cytokeratins, EMA, CEA and lysozyme.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Esophagogastric Junction. Immunohistochemistry / methods. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914488.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD34; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Keratin-7; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Tumor Suppressor Protein p53; 0 / Vimentin; EC 3.2.1.17 / Muramidase
  •  go-up   go-down


91. Ikeguchi M, Miyake T, Matsunaga T, Yamamoto M, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S, Tsujitani S: Recent results of therapy for scirrhous gastric cancer. Surg Today; 2009;39(4):290-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent results of therapy for scirrhous gastric cancer.
  • The prognosis of patients with scirrhous gastric cancer (SGC) is extremely poor.
  • This paper reviews the recent therapeutic outcomes of this type of gastric cancer and introduces a new treatment protocol for SGC.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / surgery. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):619-24 [12478012.001]
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):209-14 [9142381.001]
  • [Cites] Jpn J Clin Oncol. 2006 Aug;36(8):519-22 [16803844.001]
  • [Cites] Gastric Cancer. 1999 Aug;2(2):109-114 [11957082.001]
  • [Cites] Gastric Cancer. 2002;5(1):47-50 [12021860.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):889-95 [11221876.001]
  • [Cites] Semin Radiat Oncol. 2002 Apr;12(2):170-5 [11979418.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S25-31 [15309511.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):661-5 [16621433.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1295-304 [17225981.001]
  • [Cites] Am Surg. 1986 Sep;52(9):510-3 [3019197.001]
  • [Cites] Cancer Sci. 2004 Nov;95(11):893-900 [15546507.001]
  • [Cites] Radiology. 2004 May;231(2):421-6 [15128987.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3460-5 [17307870.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):68-78 [17591954.001]
  • [Cites] Radiology. 1990 Apr;175(1):151-4 [2156284.001]
  • [Cites] Eur J Surg. 1995 Aug;161(8):581-6 [8519874.001]
  • [Cites] Aust N Z J Surg. 1985 Dec;55(6):541-4 [3868990.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1485-8 [11100383.001]
  • [Cites] Acta Cytol. 1980 Jul-Aug;24(4):313-8 [6932143.001]
  • [Cites] Surgery. 1989 Oct;106(4):758-62; discussion 762-3 [2552599.001]
  • [Cites] Trans Am Clin Climatol Assoc. 2000;111:271-92; discussion 292-3 [10881346.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] Hepatogastroenterology. 2002 May-Jun;49(45):874-7 [12064011.001]
  • [Cites] Cancer Sci. 2005 Jun;96(6):323-32 [15958054.001]
  • [Cites] Chemotherapy. 2005 Mar;51(1):15-20 [15722628.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):3-6 [8289449.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):970-4 [8164049.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5896-901 [14676112.001]
  • [Cites] Lancet. 1992 Mar 14;339(8794):629-31 [1347336.001]
  • [Cites] Int J Clin Oncol. 2007 Aug;12(4):291-4 [17701009.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2733-8 [9704725.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):178-86; discussion 186-7 [8418695.001]
  • [Cites] Am J Surg. 2004 Sep;188(3):327-32 [15450843.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):520-6 [18029971.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1227-30 [11677936.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2048-52 [8156509.001]
  • [Cites] J Pharm Pharmacol. 2005 Feb;57(2):177-81 [15720780.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:40-4 [12775019.001]
  • [Cites] Surg Today. 2005;35(6):436-41 [15912289.001]
  • [Cites] Gastric Cancer. 2001;4(4):192-7 [11846062.001]
  • [Cites] Semin Oncol. 2003 Aug;30(4 Suppl 11):19-25 [14506600.001]
  • [Cites] Surg Today. 2007;37(11):923-43 [17952521.001]
  • [Cites] Intern Med. 1996 Dec;35(12):930-6 [9030989.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1509-12 [11677997.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):347-54 [9742917.001]
  • (PMID = 19319634.001).
  • [ISSN] 1436-2813
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


92. Müller CS, Pföhler C, Reichrath J, Tilgen W: [Gastric signet ring cell carcinoma presenting. An erysipelas-like cutaneous metastasis of the abdominal skin]. Hautarzt; 2008 Dec;59(12):992-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastric signet ring cell carcinoma presenting. An erysipelas-like cutaneous metastasis of the abdominal skin].
  • [Transliterated title] Erysipelas carcinomatosum der Abdominalhaut. "Erstmanifestation" eines Siegelringzellkarzinoms des Magens.
  • Subsequently, an extensive search for a primary adenocarcinoma uncovered a locally advanced signet-ring-cell gastric carcinoma.
  • This case shows the unusual clinical-diagnostic sequence of a patient with a signet-ring-cell-carcinoma of the stomach presenting with an erysipelas-like cutaneous metastasis of the abdominal skin.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / secondary. Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Erysipelas / diagnosis. Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male


93. Qian ZY, Miao Y, Dai CC, Xu ZK, Liu XL: [Combined multiple organ resection in 16 patients with adenocarcinoma of the body or tail of the pancreas]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Oct;27(5):572-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined multiple organ resection in 16 patients with adenocarcinoma of the body or tail of the pancreas].
  • RESULTS: Multiple organ resection was performed in 6 cases of primary pancreatic adenocarcinoma of the body and tail (3 cases of pancreatic cancer, 2 cases of malignant glucagonoma, and 1 case of well-differentiated pancreatic stromal sarcoma) and 10 cases of extrapancreatic malignancy (4 cases of gastric cancer, 2 cases of gastric leiomyosarcoma, 1 case of duodenal cancer, and 3 cases of colon cancer of hepatic flexure).
  • Patients with primary pancreatic cancer or pancreatic stromal sarcoma died within 1 year.
  • The 3-year survival rate was 70% in 10 patients with extrapancreatic malignancy, among which 2 patients with enteric cancer have survived 37 and 48 months.
  • [MeSH-major] Adenocarcinoma / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274034.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Ohi S, Takahashi N, Ninomiya K, Nakajima M, Hashimoto H, Tachibana T, Yanaga K, Ishikawa H: Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma. Hum Cell; 2007 Feb;20(1):15-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma.
  • We successfully established a spontaneously cisplatin-resistant tumor cell line (designated as IGSK-1) derived from original gastric carcinoma.
  • The histopathological diagnosis was gastric poorly differentiated adenocarcinoma accompanied with metastatic foci in lymph nodes, pT3, N2 M0, stage IIIB.
  • The susceptibility of the IGSK-1 cells to anti-cancer drugs was examined using oxygen electrode apparatus (Daikin, Tsukuba, JPN), and the results suggested TXL was effective, and CDDP, CPT-11 and 5-FU were not effective.
  • Spontaneously cisplatin-resistant gastric carcinoma cell line secreted gastrin and somatostatin is very important material for chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Stomach Neoplasms / pathology


95. Watkins BJ, Blackmun S, Kuehner ME: Gastric adenocarcinoma after Roux-en-Y gastric bypass: access and evaluation of excluded stomach. Surg Obes Relat Dis; 2007 Nov-Dec;3(6):644-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma after Roux-en-Y gastric bypass: access and evaluation of excluded stomach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastric Bypass. Obesity, Morbid / surgery. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950044.001).
  • [ISSN] 1550-7289
  • [Journal-full-title] Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • [ISO-abbreviation] Surg Obes Relat Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Zavros Y, Eaton KA, Kang W, Rathinavelu S, Katukuri V, Kao JY, Samuelson LC, Merchant JL: Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma. Oncogene; 2005 Mar 31;24(14):2354-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic gastritis in the hypochlorhydric gastrin-deficient mouse progresses to adenocarcinoma.
  • The current study tests the hypothesis that chronic atrophic gastritis from hypochlorhydria in the gastrin-deficient mouse predisposes the stomach to gastric cancer.
  • Areas of metaplasia within the G-/- mouse stomach showed decreased RUNX3 expression with elevated MUC2 and villin expression.
  • However, the cells isolated from WT, nontransformed G-/- and SOM-/- gastric tissue did not form colonies in soft agar.
  • Consistent with elevated antral proliferation, tumor tissue isolated from the G-/- mice showed elevated phosphorylated STAT3 expression.
  • We found that IFNgamma expression was also significantly higher in the tumor tissue of G-/- mice compared to WT and SOM-/- animals.
  • Therefore, we show here that in the hypochlorhydric mouse stomach, the chronic gastritis, atrophy, metaplasia, dysplasia paradigm can be recapitulated in mice.
  • Moreover, neoplastic transformation of the antral gastric mucosa does not require gastrin.


97. Furuya T, Uchiyama T, Adachi A, Okada T, Nakao M, Oga A, Yang SJ, Kawauchi S, Sasaki K: The development of a mini-array for estimating the disease state of gastric adenocarcinoma by array CGH. BMC Cancer; 2008;8:393
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development of a mini-array for estimating the disease state of gastric adenocarcinoma by array CGH.
  • The purpose of this study was to develop a BAC (bacterial artificial chromosome) mini-array allowing for the estimation of node metastasis, liver metastasis, peritoneal dissemination and the depth of tumor invasion in gastric cancers.
  • METHODS: Initially, the DNA copy number aberrations (DCNAs) were analyzed by array-based comparative genomic hybridization (aCGH) in 83 gastric adenocarcinomas as a training-sample set.
  • RESULTS: By spotting these 50 clones together with 26 frequently or rarely involved clones and 62 reference clones, a mini-array was made to estimate the above parameters, and the diagnostic performance of the mini-array was evaluated for an independent set of 30 gastric cancers (blinded - sample set).
  • CONCLUSION: These results suggest that the mini-array makes it possible to determine an optimal treatment for each of the patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Comparative Genomic Hybridization / methods. Stomach Neoplasms. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2006 Jun;15(6):1491-6 [16685384.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):545-51 [16125217.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):978-83 [16751306.001]
  • [Cites] BMC Genomics. 2006;7:278 [17074082.001]
  • [Cites] Gastric Cancer. 2007;10(1):1-11 [17334711.001]
  • [Cites] Oncology. 2007;72(1-2):132-8 [18025801.001]
  • [Cites] Cytometry. 2000 Jun 1;40(2):161-6 [10805936.001]
  • [Cites] Cytometry. 2001 Feb 15;46(1):57-62 [11241508.001]
  • [Cites] Am J Clin Pathol. 2001 Jun;115(6):828-34 [11392878.001]
  • [Cites] Jpn J Cancer Res. 2001 Jul;92(7):740-7 [11473724.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):835-9 [11830540.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3309-16 [12810664.001]
  • [Cites] J Pathol. 2003 Jul;200(3):320-6 [12845628.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3353-7 [12926075.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5137-41 [14613991.001]
  • [Cites] J Pathol. 2004 Aug;203(4):884-95 [15258990.001]
  • [Cites] Mod Pathol. 2004 Nov;17(11):1328-37 [15154013.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Cell Oncol. 2004;26(5-6):307-17 [15623941.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):247-59 [15611932.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 15;158(2):156-66 [15796963.001]
  • [Cites] Gastric Cancer. 2005;8(2):64-70 [15864711.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Aug;161(1):57-62 [16080958.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):565-71 [16794639.001]
  • (PMID = 19115996.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2637883
  •  go-up   go-down


98. Falk J, Carstens H, Lundell L, Albertsson M: Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences. Acta Oncol; 2007;46(8):1070-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of carcinoma of the oesophagus and gastric cardia. Changes over time and geographical differences.
  • BACKGROUND: The incidence of adenocarcinoma of the oesophagus is rising in many western countries including Sweden.
  • METHODS: We have studied the latest data concerning this as well as trends in the incidence of squamous cell carcinoma and adenocarcinoma of gastric cardia.
  • Data was extracted from the Swedish cancer registry and analyzed regarding gender, age, region, histology and location of tumour.
  • RESULTS: The results show an increasing incidence of adenocarcinoma in both oesophagus and gastric cardia.
  • Adenocarcinoma is now the most common histological type of cancer in the oesophageal/cardia region in Sweden.
  • Results also suggest a possible drift in location of adenocarcinoma from gastric cardia towards oesophagus.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cardia. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17851842.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


99. Haghighat P, Bekaii-Saab T: An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma. J Natl Compr Canc Netw; 2008 Oct;6(9):895-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
  • Gastric and gastroesophageal adenocarcinoma (GGA) are significant worldwide health problems.
  • [MeSH-major] Adenocarcinoma / drug therapy. Esophagogastric Junction. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926099.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Radiation-Sensitizing Agents; 0 / Taxoids; 0 / Vascular Endothelial Growth Factor A; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 5VT6420TIG / Oxonic Acid; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 44
  •  go-up   go-down


100. Fukagawa T, Sasako M, Shimoda T, Sano T, Katai H, Saka M, Mann GB, Karpeh M, Coit DG, Brennan MF: The prognostic impact of isolated tumor cells in lymph nodes of T2N0 gastric cancer: comparison of American and Japanese gastric cancer patients. Ann Surg Oncol; 2009 Mar;16(3):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic impact of isolated tumor cells in lymph nodes of T2N0 gastric cancer: comparison of American and Japanese gastric cancer patients.
  • BACKGROUND: The clinical significance of immunohistochemically detected isolated tumor cells (ITC) in lymph nodes of gastric cancer patients is controversial.
  • This study examined the prognostic impact of ITC on patients with early-stage gastric cancer in two large volume centers in the United States and Japan.
  • METHODS: Fifty-seven patients with T2N0M0 gastric carcinoma who underwent gastric resection between January 1987 and January 1997 at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and 107 patients resected at National Cancer Center Hospital (NCCH) in Tokyo between January 1984 and December 1990 were studied.
  • CONCLUSIONS: The presence of ITC detected by immunohistochemistry in the regional lymph nodes did not affect the prognosis of American and Japanese patients with T2N0M0 gastric carcinoma who underwent gastrectomy with D2 lymph node dissection.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Neoplastic Cells, Circulating / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jan;17(1):343-4; author reply 345 [19841984.001]
  • (PMID = 19137375.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down






Advertisement